



AMERICAN ACADEMY™  
OF OPHTHALMOLOGY

Protecting Sight. Empowering Lives.™

# Dry Eye Syndrome Preferred Practice Pattern®

Secretary for Quality of Care  
Timothy W. Olsen, MD

Academy Staff  
Ali Al-Rajhi, PhD, MPH  
Andre Ambrus, MLIS  
Rachel Lastra  
Flora C. Lum, MD  
Doris Mizuri

Medical Editor: Susan Garratt

Approved by: Board of Trustees  
September 22, 2018

© 2018 American Academy of Ophthalmology®  
All rights reserved

AMERICAN ACADEMY OF OPHTHALMOLOGY and PREFERRED PRACTICE PATTERN are registered trademarks of the American Academy of Ophthalmology. All other trademarks are the property of their respective owners.

Preferred Practice Pattern® guidelines are developed by the Academy's H. Dunbar Hoskins Jr., MD Center for Quality Eye Care without any external financial support. Authors and reviewers of the guidelines are volunteers and do not receive any financial compensation for their contributions to the documents. The guidelines are externally reviewed by experts and stakeholders before publication.

Correspondence:  
Ali A. Al-Rajhi, PhD, MPH, American Academy of Ophthalmology, P. O. Box 7424, San Francisco, CA 94120-7424. E-mail: [aalrajhi@aao.org](mailto:aalrajhi@aao.org).

# CORNEA/EXTERNAL DISEASE PREFERRED PRACTICE PATTERN® DEVELOPMENT PROCESS AND PARTICIPANTS

The **Cornea/External Disease Preferred Practice Pattern® Panel** members wrote the Dry Eye Syndrome Preferred Practice Pattern® guidelines (PPP). The PPP Panel members discussed and reviewed successive drafts of the document, meeting in person twice and conducting other review by e-mail discussion, to develop a consensus over the final version of the document.

## **Cornea/External Disease Preferred Practice Pattern Panel 2017–2018**

Esen K. Akpek, MD  
Guillermo Amescua, MD  
Marjan Farid, MD  
Francisco J. Garcia-Ferrer, MD  
Amy Lin, MD, Cornea Society Representative  
Michelle K. Rhee, MD  
Divya M. Varu, MD  
David C. Musch, PhD, MPH, Methodologist  
Steven P. Dunn, MD, Co-chair  
Francis S. Mah, MD, Co-chair

The **Preferred Practice Patterns Committee** members reviewed and discussed the document during a meeting in June 2018. The document was edited in response to the discussion and comments.

## **Preferred Practice Patterns Committee 2018**

Robert S. Feder, MD, Chair  
Roy S. Chuck, MD, PhD  
Steven P. Dunn, MD  
Christina J. Flaxel, MD  
Francis S. Mah, MD  
Randall J. Olson, MD  
Bruce E. Prum, Jr., MD  
David K. Wallace, MD, MPH  
David C. Musch, PhD, MPH, Methodologist

The Dry Eye Syndrome PPP was then sent for review to additional internal and external groups and individuals in July 2018. All those returning comments were required to provide disclosure of relevant relationships with industry to have their comments considered. Members of the Cornea/External Disease Preferred Practice Pattern Panel reviewed and discussed these comments and determined revisions to the document.

# FINANCIAL DISCLOSURES

In compliance with the Council of Medical Specialty Societies' Code for Interactions with Companies (available at [www.cmss.org/codeforinteractions.aspx](http://www.cmss.org/codeforinteractions.aspx)), relevant relationships with industry are listed. The Academy has Relationship with Industry Procedures to comply with the Code (available at [www.ao.org/about-preferred-practice-patterns](http://www.ao.org/about-preferred-practice-patterns)). A majority (70%) of the members of the Cornea/External Disease Preferred Practice Pattern Panel 2017–2018 had no financial relationships to disclose.

## **Cornea/External Disease Preferred Practice Pattern Panel 2017–2018**

Esen K. Akpek, MD: Allergan – Grant Support; Novartis Pharma AG, Shire – Consultant/Advisor  
 Guillermo Amescua, MD: No financial relationships to disclose  
 Steven P. Dunn, MD: No financial relationships to disclose  
 Marjan Farid, MD: Allergan, Bio-Tissue, Inc., Shire – Consultant/Advisor  
 Francisco J. Garcia-Ferrer, MD: No financial relationships to disclose  
 Amy Lin, MD: No financial relationships to disclose  
 Francis S. Mah, MD: Alcon Laboratories, Inc., Allergan, Bausch & Lomb, NovaBay, Shire, TearLab – Consultant/Advisor  
 David C. Musch, PhD, MPH: No financial relationships to disclose  
 Michelle K. Rhee, MD: No financial relationships to disclose  
 Divya M. Varu, MD: No financial relationships to disclose

## **Preferred Practice Patterns Committee 2018**

Robert S. Feder, MD: No financial relationships to disclose  
 Roy S. Chuck, MD, PhD: Novartis Pharmaceuticals, Shire – Consultant/Advisor  
 Steven P. Dunn, MD: No financial relationships to disclose  
 Christina J. Flaxel, MD: No financial relationships to disclose  
 Francis S. Mah, MD: Alcon Laboratories, Inc., Allergan, Bausch & Lomb, NovaBay, Shire, TearLab – Consultant/Advisor  
 David C. Musch, PhD, MPH: No financial relationships to disclose  
 Randall J. Olson, MD: No financial relationships to disclose  
 Bruce E. Prum, Jr., MD: No financial relationships to disclose  
 David K. Wallace, MD, MPH: No financial relationships to disclose

## **Secretary for Quality of Care**

Timothy W. Olsen, MD: No financial relationships to disclose

## **Academy Staff**

Ali Al-Rajhi, PhD, MPH: No financial relationships to disclose  
 Andre Ambrus, MLIS: No financial relationships to disclose  
 Susan Garratt: No financial relationships to disclose  
 Rachel Lastra: No financial relationships to disclose  
 Flora C. Lum, MD: No financial relationships to disclose  
 Doris Mizuiri: No financial relationships to disclose

The disclosures of relevant relationships to industry of other reviewers of the document from January to October 2018 are available online at [www.ao.org/ppp](http://www.ao.org/ppp).

# TABLE OF CONTENTS

<b>OBJECTIVES OF PREFERRED PRACTICE PATTERN GUIDELINES</b> .....	P291
<b>METHODS AND KEY TO RATINGS</b> .....	P292
<b>HIGHLIGHTED FINDINGS AND RECOMMENDATIONS FOR CARE</b> .....	P293
<b>INTRODUCTION</b> .....	P294
Disease Definition .....	P294
Patient Population.....	P294
Clinical Objectives .....	P294
<b>BACKGROUND</b> .....	P294
Prevalence and Risk Factors.....	P294
Pathogenesis .....	P296
Associated Conditions .....	P297
Natural History .....	P299
<b>CARE PROCESS</b> .....	P299
Patient Outcome Criteria .....	P299
Diagnosis .....	P299
History .....	P301
Examination.....	P302
Diagnostic Tests .....	P303
Classification of Dry Eye Syndrome.....	P306
Management .....	P306
Mild Dry Eye .....	P308
Moderate Dry Eye .....	P308
Severe Dry Eye.....	P311
Follow-up Evaluation .....	P313
Provider and Setting .....	P313
Counseling and Referral .....	P313
Socioeconomic Considerations.....	P314
<b>APPENDIX 1. QUALITY OF OPHTHALMIC CARE CORE CRITERIA</b> .....	P316
<b>APPENDIX 2. INTERNATIONAL STATISTICAL CLASSIFICATION OF DISEASES AND RELATED HEALTH PROBLEMS (ICD) CODES</b> .....	P318
<b>APPENDIX 3. SJÖGREN SYNDROME</b> .....	P319
<b>APPENDIX 4. DIAGNOSTIC TESTS</b> .....	P321
<b>LITERATURE SEARCHES FOR THIS PPP</b> .....	P324
<b>RELATED ACADEMY MATERIALS</b> .....	P326
<b>REFERENCES</b> .....	P327

# OBJECTIVES OF PREFERRED PRACTICE PATTERN® GUIDELINES

As a service to its members and the public, the American Academy of Ophthalmology has developed a series of Preferred Practice Pattern® guidelines that **identify characteristics and components of quality eye care**. Appendix 1 describes the core criteria of quality eye care.

The Preferred Practice Pattern® guidelines are based on the best available scientific data as interpreted by panels of knowledgeable health professionals. In some instances, such as when results of carefully conducted clinical trials are available, the data are particularly persuasive and provide clear guidance. In other instances, the panels have to rely on their collective judgment and evaluation of available evidence.

**These documents provide guidance for the pattern of practice, not for the care of a particular individual.** While they should generally meet the needs of most patients, they cannot possibly best meet the needs of all patients. Adherence to these PPPs will not ensure a successful outcome in every situation. These practice patterns should not be deemed inclusive of all proper methods of care or exclusive of other methods of care reasonably directed at obtaining the best results. It may be necessary to approach different patients' needs in different ways. The physician must make the ultimate judgment about the propriety of the care of a particular patient in light of all of the circumstances presented by that patient. The American Academy of Ophthalmology is available to assist members in resolving ethical dilemmas that arise in the course of ophthalmic practice.

**Preferred Practice Pattern® guidelines are not medical standards to be adhered to in all individual situations.** The Academy specifically disclaims any and all liability for injury or other damages of any kind, from negligence or otherwise, for any and all claims that may arise out of the use of any recommendations or other information contained herein.

References to certain drugs, instruments, and other products are made for illustrative purposes only and are not intended to constitute an endorsement of such. Such material may include information on applications that are not considered community standard, that reflect indications not included in approved US Food and Drug Administration (FDA) labeling, or that are approved for use only in restricted research settings. The FDA has stated that it is the responsibility of the physician to determine the FDA status of each drug or device he or she wishes to use, and to use them with appropriate patient consent in compliance with applicable law.

Innovation in medicine is essential to ensure the future health of the American public, and the Academy encourages the development of new diagnostic and therapeutic methods that will improve eye care. It is essential to recognize that true medical excellence is achieved only when the patients' needs are the foremost consideration.

All Preferred Practice Pattern® guidelines are reviewed by their parent panel annually or earlier if developments warrant and updated accordingly. To ensure that all PPPs are current, each is valid for 5 years from the "approved by" date unless superseded by a revision. Preferred Practice Pattern guidelines are funded by the Academy without commercial support. Authors and reviewers of PPPs are volunteers and do not receive any financial compensation for their contributions to the documents. The PPPs are externally reviewed by experts and stakeholders, including consumer representatives, before publication. The PPPs are developed in compliance with the Council of Medical Specialty Societies' Code for Interactions with Companies. The Academy has Relationship with Industry Procedures (available at [www.aao.org/about-preferred-practice-patterns](http://www.aao.org/about-preferred-practice-patterns)) to comply with the Code.

Appendix 2 contains the International Statistical Classification of Diseases and Related Health Problems (ICD) codes for the disease entities that this PPP covers. The intended users of the Dry Eye Syndrome PPP are ophthalmologists.

## METHODS AND KEY TO RATINGS

Preferred Practice Pattern® guidelines should be clinically relevant and specific enough to provide useful information to practitioners. Where evidence exists to support a recommendation for care, the recommendation should be given an explicit rating that shows the strength of evidence. To accomplish these aims, methods from the Scottish Intercollegiate Guideline Network<sup>1</sup> (SIGN) and the Grading of Recommendations Assessment, Development and Evaluation<sup>2</sup> (GRADE) group are used. GRADE is a systematic approach to grading the strength of the total body of evidence that is available to support recommendations on a specific clinical management issue. Organizations that have adopted GRADE include SIGN, the World Health Organization, the Agency for Healthcare Research and Quality, and the American College of Physicians.<sup>3</sup>

- ◆ All studies used to form a recommendation for care are graded for strength of evidence individually, and that grade is listed with the study citation.
- ◆ To rate individual studies, a scale based on SIGN<sup>1</sup> is used. The definitions and levels of evidence to rate individual studies are as follows:

I++	High-quality meta-analyses, systematic reviews of randomized controlled trials (RCTs), or RCTs with a very low risk of bias
I+	Well-conducted meta-analyses, systematic reviews of RCTs, or RCTs with a low risk of bias
I-	Meta-analyses, systematic reviews of RCTs, or RCTs with a high risk of bias
II++	High-quality systematic reviews of case-control or cohort studies High-quality case-control or cohort studies with a very low risk of confounding or bias and a high probability that the relationship is causal
II+	Well-conducted case-control or cohort studies with a low risk of confounding or bias and a moderate probability that the relationship is causal
II-	Case-control or cohort studies with a high risk of confounding or bias and a significant risk that the relationship is not causal
III	Nonanalytic studies (e.g., case reports, case series)

- ◆ Recommendations for care are formed based on the body of the evidence. The body of evidence quality ratings are defined by GRADE<sup>2</sup> as follows:

Good quality	Further research is very unlikely to change our confidence in the estimate of effect
Moderate quality	Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate
Insufficient quality	Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate Any estimate of effect is very uncertain

- ◆ Key recommendations for care are defined by GRADE<sup>2</sup> as follows:

Strong recommendation	Used when the desirable effects of an intervention clearly outweigh the undesirable effects or clearly do not
Discretionary recommendation	Used when the trade-offs are less certain—either because of low-quality evidence or because evidence suggests that desirable and undesirable effects are closely balanced

- ◆ The Highlighted Findings and Recommendations for Care section lists points determined by the PPP panel to be of particular importance to vision and quality of life outcomes.
- ◆ All recommendations for care in this PPP were rated using the system described above. Ratings are embedded throughout the PPP main text in italics.
- ◆ Literature searches to update the PPP were undertaken in February 2017 and June 2018 in PubMed and the Cochrane Library. Complete details of the literature search are available at [www.aao.org/ppp](http://www.aao.org/ppp).

## HIGHLIGHTED FINDINGS AND RECOMMENDATIONS FOR CARE

---

Dry eye is a common ocular condition that has a substantial impact on the quality of life of afflicted individuals owing to discomfort and visual disability. Dry eye may compromise results of corneal, cataract, and refractive surgery.

---

No single test is adequate for establishing the diagnosis of dry eye. The constellation of findings from multiple tests can add greatly to the clinician's understanding of the patient's condition.

---

Pharmacological and procedural treatments are associated with improvements in patient symptoms and clinical signs, although chronic therapy and patient compliance are necessary in most instances.

---

Omega-3 fatty acid products without ethyl esters have been recommended and widely used in the treatment of dry eye. However, a prospective, multicenter, masked large-scale trial of 3000 mg of omega-3 fatty acids for 12 months did not show any benefit in patient symptoms or signs over placebo.<sup>4</sup>

---

Topical cyclosporine treatment has long been used in the treatment of dry eye and shown to have clinical benefits. Topical cyclosporine, in some instances, leads to long-term treatment-free remission of patient symptoms and signs.<sup>5,6</sup>

Lifitegrast is a lymphocyte function-associated antigen-1 antagonist developed to treat dry eye syndrome (also known as dry eye disease), but the exact mechanism of action of lifitegrast in dry eye is unknown. Topical lifitegrast 5% has been approved by the US Food and Drug Administration for treatment of dry eye. Published studies show benefit in signs (corneal and conjunctival staining) as well as symptoms (eye dryness score and ocular discomfort) over a period of 3 months.<sup>7-9</sup> Although the drug seems to be safe over 12 months, long-term efficacy and side effects are unknown.<sup>10</sup>

---

Dry eye patients considering keratorefractive surgery, particularly LASIK, should be cautioned that the dry eye condition could become worse after surgery. Dry eye symptoms are common in the first few months after surgery and tend to subside with time. Patients can safely undergo LASIK surgery if a pre-existing dry eye condition can be improved preoperatively.

---

Dry eye is one of the main reasons for patient dissatisfaction following cataract surgery.<sup>11</sup> Dry eye symptoms that continue beyond the normal postoperative period of 3 months might be seen in about one third of individuals.<sup>12</sup> Baseline ocular surface and tear film parameters predict the patients at risk.<sup>13</sup> Therefore, all patients undergoing cataract surgery should be evaluated and managed for dry eye preoperatively.

---

Approximately 1/10 patients with clinically significant dry eye have an underlying Sjögren syndrome. A recent meta-analysis found that, among autoimmune diseases, primary Sjögren syndrome is the most strongly associated risk factor for malignancy, with an incidence rate of 18.9% (95% CI, 9.4–37.9).<sup>14</sup> Therefore timely diagnosis and appropriate management of patients with underlying Sjögren syndrome is relevant.

---



# INTRODUCTION

## DISEASE DEFINITION

Dry eye disease (also known as dry eye syndrome) refers to a group of disorders of the tear film that are due to reduced tear production or tear film instability, associated with ocular discomfort and/or visual symptoms and inflammatory disease of the ocular surface.

## PATIENT POPULATION

The patient population includes individuals of all ages who present with symptoms and signs suggestive of dry eye, such as ocular irritation, redness, mucus discharge, fluctuating vision, and decreased tear meniscus or plugged meibomian glands.

## CLINICAL OBJECTIVES

- ◆ Establish the diagnosis of dry eye and differentiate it from other causes of ocular irritation and redness that may complicate both patient care and research on tear deficiency
- ◆ Identify the local and systemic causes of dry eye disease
- ◆ Recommend appropriate therapy
- ◆ Relieve discomfort
- ◆ Prevent worsening of symptoms and clinical findings
- ◆ Educate and involve the patient in the management of this disease

# BACKGROUND

Dry eye, either alone or in combination with other conditions, is a frequent cause of ocular irritation that leads patients to seek ophthalmologic care.<sup>15</sup> Even though these symptoms often improve with treatment, the disease usually is not curable, which may be a source of patient and physician frustration. Importantly, dry eye is also a cause of reduced visual function<sup>16-19</sup> and may compromise results of corneal, cataract, and refractive surgery.

## PREVALENCE AND RISK FACTORS

Epidemiologic information on dry eye disease has been limited by lack of uniformity in its definition and the inability of any single diagnostic test or set of diagnostic tests to confirm or rule out the condition. Dry eye disease is a common condition that causes varying degrees of discomfort and visual disability. Although clinic-based studies confirm its frequency

(17% of 2127 consecutive new outpatients were diagnosed with dry eye following comprehensive examination), such studies may not reflect the overall population.<sup>20</sup> A population-based study of dry eye conducted in Melbourne, Australia, reported that of the 926 participants aged 40 to 97 years, 16.3% had a low Schirmer test ( $\leq 8$  mm) and 10.8% had a high rose bengal score ( $\geq 4$  mm).<sup>21</sup> The prevalence of self-reported dry eye in 3722 participants of the Beaver Dam (Wisconsin) Eye Study varied from 8.4% of subjects younger than 60 to 19.0% of those over 80, with an overall prevalence of 14.4%.<sup>22</sup> The Men's Health Study revealed that the prevalence of dry eye in men increased from 3.9% to 7.7% when men aged 50 to 54 were compared with men over 80 ( $n = 25,444$ ). In this study, dry eye was defined as a reported clinical diagnosis or symptoms of both dryness and irritation either constantly or often.<sup>23</sup> In a similar Women's Health Study of over 39,000 women, the prevalence of dry eye was 5.7% among women younger than 50 and increased to 9.8% among women over 75. In this survey, the definition used for dry eye was the same as for the Men's Health Study.<sup>24</sup> In a clinic setting, 224 subjects identified with dry eye were far more likely to exhibit signs of evaporative dry eye resulting from meibomian gland dysfunction (MGD) than from pure aqueous deficient dry eye.<sup>25</sup>

Estimates of dry eye prevalence based on treatment-derived data yield much lower percentages. A study evaluating medical claims data for nearly 10 million enrollees in managed care plans found that dry eye was diagnosed or treated with punctal occlusion in 0.4% to 0.5% of the enrollees.<sup>23,24,26</sup>

Many risk factors for dry eye have been proposed. Older age and female gender have been identified as major risk factors.<sup>21,22,26-29</sup> A Japanese study found an increased prevalence of dry eye disease among Japanese office workers using visual display terminals.<sup>30</sup> Concurrent use of glaucoma medication containing benzalkonium chloride (BAK) was also shown to be a risk factor in patients.<sup>31,32</sup> Rheumatoid arthritis was associated with dry eye in two studies.<sup>21,22</sup> The Beaver Dam Eye Study found that after controlling for age and gender, smoking and multivitamin use were associated with an increased risk of dry eye, whereas caffeine use was associated with a decreased risk.<sup>22</sup> An update to the Beaver Dam Study<sup>29</sup> found that additional risk factors for dry eye included the use of antihistamines, antidepressant and anti-anxiety medications, and oral corticosteroids. Angiotensin-converting enzyme inhibitors were associated with a lower risk. Among the 25,665 postmenopausal women in the Women's Health Study, hormone replacement therapy, and, in particular, estrogen use alone, was associated with an increased risk of clinically diagnosed dry eye disease or severe symptoms.<sup>33</sup> More recent reports have suggested a relationship between botulinum toxin injection and dry eye.<sup>34-36</sup> A recent large community-based study from

China found a 17.5% prevalence of dry eye among patients with diabetes (mean age 68.9 ± 8.9 years old), particularly those with poor metabolic control.<sup>37</sup>

**PATHOGENESIS**

The ocular surface and tear-secreting glands function as an integrated unit.<sup>38</sup> Disease or dysfunction of this functional unit results in an unstable and poorly maintained tear film that causes ocular irritation symptoms and possible damage to the ocular surface epithelium. Dysfunction of this integrated unit may develop as a result of aging, a decrease in supportive factors (such as androgen hormones), blink abnormalities, systemic inflammatory diseases (e.g., Sjögren syndrome, autoimmune thyroid disease, or rheumatoid arthritis), ocular surface diseases (e.g., herpes simplex virus [HSV] keratitis) or surgeries that disrupt the trigeminal afferent sensory nerves (e.g., laser-assisted in situ keratomileusis [LASIK]), and systemic diseases or medications that disrupt the efferent cholinergic nerves that stimulate tear secretion.<sup>39</sup> Decreased tear secretion and clearance initiates an inflammatory response on the ocular surface that involves both soluble and cellular mediators.<sup>40,41</sup> Clinical and basic research suggests that this inflammation plays a role in the pathogenesis of dry eye (see Figure 1).<sup>42,43</sup>




FIGURE 1. INFLAMMATORY MEDIATORS IN DRY EYE  
 Modified with permission from Craig JP et al. TFOS DEWS II report executive summary. *Ocul Surf.* 2017;15:802-812.

## ASSOCIATED CONDITIONS

Symptoms caused by dry eye may be exacerbated by the use of systemic medications such as diuretics, antihistamines, anticholinergics, antidepressants, and systemic retinoids (e.g., isotretinoin).<sup>22,23,29,31,44-47</sup> Instillation of any eye medications, especially when they are instilled frequently (e.g., more than four drops a day), may prevent the normal maintenance of the tear film and cause dry eye symptoms due to preservatives. In addition, environmental factors, such as reduced humidity and increased wind, drafts, air conditioning, or heating may exacerbate the ocular discomfort of patients with dry eye. Exogenous irritants and allergens, although not believed to be causative of dry eye, may also aggravate the symptoms.

Rosacea can exacerbate the symptoms of dry eye and ocular surface disease. Rosacea is a disease of the skin and eye that is observed more frequently in fair-skinned individuals,<sup>48</sup> but it can occur in people of all skin types. Characteristic facial skin findings include erythema, telangiectasia, papules, pustules, prominent sebaceous glands, and rhinophyma. Rosacea may be challenging to diagnose in patients with darker skin tones because it is difficult to visualize telangiectasia or facial flushing<sup>48</sup> and in children, since ocular symptoms can appear before the cutaneous symptoms of rosacea do, leading to misdiagnosis.<sup>49,50</sup> While rosacea is more prevalent in women, it can be more severe when it occurs in men.<sup>51,52</sup> Because many patients exhibit only mild signs, such as telangiectasia and a history of easy facial flushing, the diagnosis of rosacea is often overlooked, especially in children who may present with ocular findings, such as chronic recurrent blepharokeratoconjunctivitis, punctate erosions, peripheral keratitis, MGD, or recurrent chalazia, and who have subtle signs of rosacea prior to cutaneous manifestations.<sup>53</sup> Children with ocular rosacea often present with corneal involvement and asymmetry of ocular disease, and the potential for sight-threatening visual impairment should be considered. Cutaneous rosacea is less frequent in children, and associated atopy is common.<sup>54,55</sup> Children with a history of styes have an increased risk of developing adult rosacea.<sup>56</sup>

When there is an associated systemic disease such as Sjögren syndrome, an inflammatory cellular infiltration of the exocrine glands (including lacrimal gland) leads to saliva- and tear-production deficiency (see Appendix 3). About 10% of patients with clinically significant aqueous deficient dry eye have an underlying primary Sjögren syndrome.<sup>57,58</sup> Primary Sjögren syndrome is a multisystem disorder with systemic involvement and increased risk of lymphoma.<sup>59</sup> About 5% of patients with Sjögren syndrome will develop some form of lymphoid malignancy.<sup>60</sup> A recent meta-analysis found that among rheumatic diseases, primary Sjögren syndrome is the risk factor most strongly associated with

malignancy, with an incidence rate of 18.9% (95% CI, 9.4–37.9). This implies an increased incidence of 320 cases per 100,000 patient-years.<sup>14</sup> Therefore, ophthalmologists caring for patients with clinically significant dry eye should have a high index of suspicion for Sjögren syndrome and a low threshold for serological work-up for diagnostic purposes.

Aqueous tear deficiency may develop in other systemic conditions such as lymphoma, sarcoidosis,<sup>61,62</sup> hemochromatosis, and amyloidosis<sup>63</sup> that results in infiltration of the lacrimal gland and replacement of the secretory acini. Dry eye may develop in patients with systemic viral infections; it has been reported in patients infected by the retroviruses, Epstein-Barr virus,<sup>64</sup> human T-cell lymphotropic virus type 1, and human immunodeficiency virus (HIV).<sup>65</sup> Dry eye was diagnosed in 21% of a group of patients with AIDS,<sup>66</sup> and a condition known as diffuse infiltrative lymphadenopathy syndrome has been reported in patients with HIV infection, most of whom were children.<sup>65</sup> Decreased tear secretion and reduced tear concentrations of lactoferrin have been reported in patients with hepatitis C.<sup>67,68</sup> Lacrimal gland swelling, dry eye, and Sjögren syndrome have been associated with primary and persistent Epstein-Barr virus infections.<sup>64,69-71</sup> Severe dry eye has been reported in recipients of hematopoietic stem cell transplants with or without the development of graft-versus-host disease (GVHD).<sup>72,73</sup> In chronic GVHD, there is infiltration and fibrosis of the lacrimal glands and conjunctiva as a result of T-cell interaction with fibroblasts.<sup>72,74,75</sup> Diseases such as ocular mucous membrane pemphigoid and Stevens-Johnson syndrome produce tear deficiency as a result of inflammation, scarring, and destruction of the conjunctival goblet cells. Atopy may produce dry eye that results from blepharitis, conjunctival scarring, or antihistamine use. More generally, since dry eye is known to be most common in postmenopausal women, its occurrence in younger patients and males should be viewed with suspicion of systemic or local associated conditions.

Eyelid conditions associated with dry eye include eyelid malposition, lagophthalmos, exophthalmos, thyroid-associated ocular disease, and blepharitis as well as neuromuscular disorders that affect blinking (e.g., Parkinson disease, Bell's palsy).<sup>76</sup> The influence of blinking on the tear film and ocular surface is an area of current research. Recently, incomplete blinking was shown to be associated with a two-fold increase in evaporative dry eye with greater levels of meibomian gland dropout as well as poor meibum quality tear film lipid-layer thickness.<sup>77</sup> Orbital/eyelid surgery, radiation, and injury may also lead to dry eye. Increased screen time (e.g. video monitor, television, cellular phones, etc.) may reduce blink rate and may exacerbate dry eye and ocular surface disease in adults and in children.<sup>78</sup>

## NATURAL HISTORY

Dry eye varies in severity, duration, and etiology.<sup>79</sup> In the majority of patients, the condition is not sight-threatening and is characterized by fluctuating vision and troublesome symptoms of irritation that are usually worse at the end of the day. In some individuals, exacerbating factors such as systemic medications that decrease tear production or environmental conditions that increase tear film instability may lead to an acute increase in the severity of symptoms. Elimination of such factors often leads to marked improvement and may even be curative. The disease may exhibit chronicity, characterized by fluctuating severity of symptoms and/or a gradual increase in symptom severity with time.

Reversible conjunctival squamous metaplasia and punctate epithelial erosions of the conjunctiva and cornea, diagnosed by performing ocular surface dye staining, develop in many patients who have clinically significant dry eye. Patients with severe dry eye and underlying inflammatory systemic conditions may develop complications such as ocular surface keratinization, corneal scarring, thinning, or neovascularization, microbial or sterile corneal ulceration with possible perforation, and severe visual loss.<sup>80</sup>

## CARE PROCESS

### PATIENT OUTCOME CRITERIA

Outcome criteria for treating dry eye include the following:

- ◆ Reduce or alleviate signs and symptoms of dry eye, such as ocular irritation, redness, or mucous discharge
- ◆ Maintain or improve visual function
- ◆ Reduce or prevent ocular surface damage

### DIAGNOSIS

Many ocular surface diseases produce symptoms that are similar to those associated with dry eye, including foreign body sensation, mild itching, irritation, and soreness. Identifying characteristics of the causative factors, such as adverse environments (e.g., air travel, sitting near an air conditioner vent, low humidity), prolonged visual efforts (e.g., reading, computer use), or symptomatic relief with the use of artificial tears is helpful in diagnosing dry eye. Supporting clinical observations and tests are used to confirm the diagnosis. A diagnostic classification scheme is shown in Figure 2.




FIGURE 2. CLASSIFICATION OF DRY EYE DISEASE

Reproduced with permission from Craig JP et al. TFOS DEWS II report executive summary. *Ocul Surf.* 2017;15:802-812.

DED = dry eye disease (also known as dry eye syndrome); OSD = ocular surface disease.

In 2017, the International Dry Eye Workshop (DEWS) II published its report on dry eye following an enormous effort by more than 150 dry eye experts and scientists to study multiple aspects of dry eye disease and to clarify the definition of the disease. They reviewed a decade of updated publications were reviewed for this second-consensus, 10-publication effort. Of note, the effort was initiated by the Tear Film and Ocular Surface Society (TFOS) and obtained unrestricted industry donations to complete the 2-year task.<sup>81</sup>

Participants in DEWS II agreed that the two major factors, deficient aqueous tear production and tear film instability, may cause dry eye independently. Those factors may also be present together and both contribute to dry eye symptoms and signs. Recent evidence suggests that tear film instability is more common than a combined-mechanism dry eye. Aqueous tear deficiency alone is the least common presentation of dry eye.<sup>25</sup> However, it remains important because it can be associated with underlying systemic inflammatory/autoimmune diseases. Most patients have multiple factors contributing to dry eye. Many conditions, such

as neurotrophic keratitis after HSV infection or LASIK, include aspects of decreased tear production and increased evaporative loss.

## History

Questions about the following elements of the patient history may elicit helpful information. There are several questionnaires that may be useful in completing the patient history.<sup>50,82</sup>

- ◆ Symptoms and signs (e.g., irritation, tearing, burning, stinging, dry or foreign body sensation, mild itching, photophobia, blurry vision, contact lens intolerance, redness, mucous discharge, increased frequency of blinking, eye fatigue, diurnal fluctuation, symptoms that worsen later in the day)
- ◆ Exacerbating conditions (e.g., wind, air travel, decreased humidity, prolonged visual efforts associated with decreased blink rate such as reading and using the computer)
- ◆ Duration of symptoms

The ocular history may include recording information about the following:

- ◆ Topical medications and their associated preservatives (e.g., artificial tears, eyewash, antihistamines, glaucoma medications, vasoconstrictors, corticosteroids, antiviral medications, homeopathic or herbal preparations), which should be discussed and considered
- ◆ Contact lens history
- ◆ Allergic conjunctivitis
- ◆ Ocular surgical history (e.g., prior keratoplasty, cataract surgery, keratorefractive surgery)
- ◆ Ocular surface disease (e.g., HSV, varicella zoster virus, ocular mucous membrane pemphigoid, aniridia)
- ◆ Punctal surgery
- ◆ Eyelid surgery (e.g., prior ptosis repair, blepharoplasty, entropion/ectropion repair)
- ◆ Bell's palsy

The medical history may take into account the following elements:

- ◆ Smoking or exposure to second-hand smoke
- ◆ Dermatological diseases (e.g., rosacea, psoriasis, varicella zoster virus)
- ◆ Technique and frequency of facial washing, including eyelid and eyelash hygiene
- ◆ Atopy



- ◆ Systemic inflammatory diseases (e.g., Sjögren syndrome, GVHD, rheumatoid arthritis, systemic lupus erythematosus, Stevens-Johnson syndrome, sarcoidosis, scleroderma)
- ◆ Other systemic conditions (e.g., lymphoma, sarcoidosis)
- ◆ Systemic medications (e.g., antihistamines, diuretics, hormones and hormonal antagonists, antidepressants, cardiac antiarrhythmic drugs, isotretinoin, diphenoxylate/atropine, beta-adrenergic antagonists, chemotherapy agents, any other drug with anticholinergic effects)
- ◆ Trauma (e.g., mechanical, chemical, thermal)
- ◆ Chronic viral infections (e.g., hepatitis C, HIV)
- ◆ Nonocular surgery (e.g., bone-marrow transplant, head and neck surgery, trigeminal neuralgia surgery)
- ◆ Orbital radiation
- ◆ Neurological conditions (e.g., Parkinson disease, Bell's palsy, Riley-Day syndrome, trigeminal neuralgia)
- ◆ Nonocular symptoms:
  - Dry mouth, dental cavities, oral ulcers
  - Fatigue
  - Joint pain/muscle ache
  - Menopause

## Examination

All patients should have a comprehensive adult medical eye evaluation at the recommended intervals.<sup>83</sup> This should include the evaluation of tear film and ocular surface, particularly in preoperative cataract and refractive surgery patients. Additional evaluation of a patient who presents with symptoms suggestive of dry eye should include further testing relevant to dry eye.<sup>83</sup>

The purpose of the external examination and the slit-lamp biomicroscopy is to do the following:

- ◆ Document the signs of dry eye
- ◆ Assess the quality, quantity, and stability of the tear film
- ◆ Determine other causes of ocular irritation

The external examination should pay particular attention to the following:

- ◆ Skin (e.g., scleroderma, facial changes consistent with rosacea, seborrhea)

- ◆ Eyelids: incomplete closure/malposition, incomplete or infrequent blink, eyelid lag or retraction, erythema of eyelid margins, abnormal deposits or secretions, entropion, ectropion
- ◆ Adnexa: enlargement of the lacrimal glands
- ◆ Proptosis
- ◆ Cranial nerve function (e.g., cranial nerve V [trigeminal], cranial nerve VII [facial])
- ◆ Hands: joint deformities characteristic of rheumatoid arthritis, Raynaud phenomenon, splinter hemorrhages underneath the nails

The slit-lamp biomicroscopy evaluation should focus on the following:

- ◆ Tear film: height of the meniscus along the inferior eyelid, debris, increased viscosity, mucous strands, and foam, break-up time and pattern
- ◆ Eyelashes: trichiasis, distichiasis, madarosis, deposits
- ◆ Anterior and posterior eyelid margins: abnormalities of meibomian glands (e.g., orifice metaplasia, reduced expressible meibum, atrophy), character of meibomian gland secretions (e.g., turbid, thickened, foamy, deficient), vascularization crossing the mucocutaneous junction, keratinization, scarring, eyelid margin hyperemia
- ◆ Puncta: patency and position, presence and position of plugs
- ◆ Conjunctiva:
  - ◆ Inferior fornix and tarsal conjunctiva (e.g., mucous threads, scarring, erythema, papillary reaction, follicle enlargement, keratinization, subepithelial fibrosis, foreshortening, symblepharon)
  - ◆ Bulbar conjunctiva (all four quadrants) (e.g., punctate staining with rose bengal, lissamine green, or fluorescein dyes; hyperemia; localized drying; keratinization, chemosis, chalasis, follicles). Lissamine green may provide higher yield in the conjunctiva.
- ◆ Cornea: localized interpalpebral drying, punctate epithelial erosions assessed with fluorescein dye, punctate staining with rose bengal or fluorescein dyes, filaments, epithelial defects, basement membrane irregularities, mucous plaques, keratinization, pannus formation, thinning, infiltrates, ulceration, scarring, neovascularization, evidence of corneal or refractive surgery

## Diagnostic Tests

A detailed review of systems should be performed for any patient who has clinically significant dry eye. Diagnostic testing is based on the review of systems and other clinical findings. A high degree of suspicion for Sjögren syndrome is appropriate in

patients who have clinically significant dry eye and dry mouth symptoms. For patients who are suspected of having a Sjögren syndrome, a serological examination for anti-Sjögren syndrome A antibody (SSA or anti-Ro), anti-Sjögren syndrome B antibody (SSB or anti-La), rheumatoid factor, and antinuclear antibody should be ordered. A new point-of-care test is now available that includes the traditional serology as well as additional biomarkers (salivary protein 1 [SP1], carbonic anhydrase 6 [CA6] and parotid secretory protein [PSP]) for Sjögren syndrome. Additional studies are needed to determine if these biomarkers, especially CA6, are indicators of early Sjögren syndrome or another form of autoimmune dry eye disease.<sup>84</sup>

Patients who might have thyroid eye disease should be tested for antithyroid peroxidase antibody and antithyroglobulin antibody. Orbital imaging, such as a CT or MRI scans, can be used to assess extraocular muscle thickens in patients who have thyroid disease. Conjunctival biopsy is appropriate for any patients who have significant chronic conjunctivitis with a nodular appearance or cicatrization (subepithelial fibrosis or fornix foreshortening). Table 1 summarizes the diagnostic tests ordered for possible underlying systemic conditions in patients with dry eye.

Tear osmolarity has been thought to be an indicator of dry eye disease,<sup>85</sup> and a commercial device is available for clinicians. Several studies using this device have demonstrated tear hyperosmolarity and/or significant inter-eye osmolarity differences in patients with aqueous tear deficiency or evaporative dry eye,<sup>86,87</sup> and it has been approved by the US Food and Drug Administration (FDA) for use as a point-of-care laboratory test to diagnose dry eye. Tear film osmolarity levels show variable association with clinical signs or symptoms, making the results of this test occasionally difficult to interpret.<sup>88,89</sup> The test results should be considered within the context of symptoms and other clinical findings. Rather than relying solely on a single measure of tear osmolarity, correlation with clinical findings or differences in osmolarity over time or under different conditions is more informative for confirming the diagnosis of dry eye. Indeed, most recent studies confirm that normal subjects have exceptionally stable tear film osmolarity, whereas tear osmolarity values in dry eye subjects become unstable quickly and lose homeostasis with environmental changes.<sup>85</sup> These data reinforce the long-held belief that tear film instability due to increased evaporation of tears resulting in hyperosmolarity (i.e., evaporative dry eye) is a core mechanism of the disease. (See Appendix 4 for additional information about diagnostic tests.)

TABLE 1 DIAGNOSTIC TESTS ORDERED FOR POSSIBLE UNDERLYING SYSTEMIC CONDITIONS IN PATIENTS WITH DRY EYE

Suspected Underlying Condition	Diagnostic Testing
Sjögren syndrome	SSA, SSB, ANA, RF, SP1, CA6, PSP
Thyroid eye disease	Antithyroid peroxidase antibody, antithyroglobulin antibody, orbital imaging (CT or MRI scan)
Sarcoidosis	Serum lysozyme, ACE, chest CT to determine extent of disease (consult with a pulmonologist as necessary), conjunctival biopsy <sup>91</sup>
Ocular mucous membrane pemphigoid	Conjunctival biopsy with light microscopic as well as immunofluorescent or immunohistochemical studies

ACE = angiotensin-converting enzyme; ANA = antinuclear antibody; CA6 = carbonic anhydrase 6; CT = computed tomography; PSP = parotid secretory protein; RF = rheumatoid factor; SP1 = salivary protein 1; SSA = anti-Sjögren syndrome A antibody (anti-Ro); SSB = anti-Sjögren syndrome B antibody (anti-La)

A commercially available point-of-care matrix metalloproteinase-9 (MMP-9) test can also be used as an aid in the diagnosis of dry eye. The qualitative nature of this test can be used to assess change in the disease state. Although the test does not differentiate dry eye from other inflammatory ocular surface diseases, it may aid in the management.<sup>90</sup>

A rapid tear break-up time may indicate an unstable tear film with normal aqueous tear production, and there may be minimal or no dye staining of the ocular surface.<sup>92</sup>

The workup for ocular surface disease includes one or more of the following tests: osmolarity, MMP-9, Schirmer without anesthesia, fluorescein dye disappearance, tear break-up time, ocular surface dye staining (with rose bengal, fluorescein, and/or lissamine green), and lacrimal gland function. If Schirmer with anesthesia is considered, several minutes should be allowed between the dye testing and the Schirmer test. Table 2 lists characteristic findings for each diagnostic test for each condition. Corneal sensation should be assessed when trigeminal nerve dysfunction is suspected.<sup>93</sup> A laboratory and clinical evaluation for autoimmune disorders should be considered for patients with significant dry eye accompanied by other signs and symptoms of an autoimmune disorder (e.g., dry mouth), or a family history of an autoimmune disorder.

TABLE 2 CHARACTERISTIC FINDINGS FOR DRY EYE DISEASE DIAGNOSTIC TESTS

Test	Characteristic Findings
Tear osmolarity	Elevated; test-to-test variability; intereye differences considered abnormal <sup>86-89</sup>
Matrix metalloproteinase-9	Indicates presence of inflammation which dictates treatment
Aqueous tear production (Schirmer test)	10 mm or less considered abnormal <sup>94,95</sup>
Fluorescein dye disappearance test/tear function index	Test result is compared with a standard color scale <sup>96</sup>
Tear break-up time	Less than 10 seconds considered abnormal
Ocular surface dye staining	Staining of inferior cornea and bulbar conjunctiva typical
Lacrimal gland function	Decreased tear lactoferrin concentrations

## CLASSIFICATION OF DRY EYE DISEASE

Dry eye is generally classified according to a combination of symptoms and signs. In this PPP, dry eye is classified as mild, moderate, and severe based on both symptoms and signs, but with an emphasis on symptoms over signs.<sup>97</sup> Owing to the nature of dry eye disease, this classification is imprecise because characteristics at each level overlap.

Patients with mild dry eye disease may have symptoms of irritation, itching, soreness, ocular discomfort, burning, or intermittent blurred vision. The diagnosis of dry eye in its mild form is difficult to make because of the inconsistent correlation between reported symptoms and clinical signs.<sup>98</sup> Patients can identify ocular dysesthesia related to contact lens wear or other cause as dryness, even when tear function is normal.<sup>99,100</sup> More effective relief of patient symptoms can be achieved if the ophthalmologist can differentiate conditions related to dry eye from other causes. Because most dry eye conditions have a chronic course, repeated observation and reporting of symptoms over time will allow clinical diagnosis of dry eye in most cases.

Patients with moderate dry eye disease have increased discomfort and frequency of symptoms, and the negative effect on visual function may become more consistent.

Patients with severe dry eye disease have an increasing frequency of visual symptoms that may become constant as well as potentially disabling.

Dry eye disease is also categorized into one of two forms, aqueous tear deficiency and evaporative. These conditions coexist in the majority of the patients with the disease.

## MANAGEMENT

Patients with dry eye symptoms often have many contributory factors. It is imperative to treat any causative factors that are amenable to treatment. Tear replacement is frequently unsuccessful when used as the sole treatment if additional causative factors are not concomitantly addressed.

Patient education is an important aspect of successful management of this condition. The ophthalmologist should educate the patient about the natural history and chronic nature of dry eye. Realistic expectations for therapeutic goals should be set and discussed with the patient. Patient education is an important aspect of successful management of this condition.

Table 3 lists treatments of dry eye disease according to the severity level of the disease. Specific therapies may be chosen from any category regardless of the level of disease severity, depending on physician experience and patient preference.

TABLE 3 STAGED MANAGEMENT AND TREATMENT RECOMMENDATIONS FOR DRY EYE DISEASE\*†‡

## Step 1

- Education regarding the condition, its management, treatment, and prognosis
- Modification of local environment
- Education regarding potential dietary modifications (including oral essential fatty acid supplementation)
- Identification and potential modification/elimination of offending systemic and topical medications
- Ocular lubricants of various types (if MGD is present, then consider lipid-containing supplements)
- Lid hygiene and warm compresses of various types

## Step 2

If the above options are inadequate consider:

- Nonpreserved ocular lubricants to minimize preservative-induced toxicity
- Tea tree oil treatment for *Demodex* (if present)
- Tear conservation
  - Punctal occlusion
  - Moisture chamber spectacles/goggles
- Overnight treatments (such as ointment or moisture chamber devices)
- In-office, physical heating and expression of the meibomian glands (including device-assisted therapies, such as LipiFlow, or intense pulse light treatment)
- In-office intense pulsed light therapy for MGD
- Prescription drugs to manage DED§
  - Topical antibiotic or antibiotic/steroid combination applied to the lid margins for anterior blepharitis (if present)
  - Topical corticosteroid (limited-duration)
  - Topical secretagogues
  - Topical nonglucocorticoid immunomodulatory drugs (such as cyclosporine)
  - Topical LFA-1 antagonist drugs (such as lifitegrast)
  - Oral macrolide or tetracycline antibiotics

## Step 3

If the above options are inadequate consider:

- Oral secretagogues
- Autologous/allogeneic serum eye drops
- Therapeutic contact lens options
  - Soft bandage lenses
  - Rigid scleral lenses

## Step 4

If the above options are inadequate consider:

- Topical corticosteroid for longer duration
- Amniotic membrane grafts
- Surgical punctal occlusion
- Other surgical approaches (e.g., tarsorrhaphy, salivary gland transplantation)

Reproduced with permission from Jones et al. TFOS DEWS II management and therapy report. *Ocul Surf.* 2017;15(3):609.

DED = dry eye disease; LFA-a = lymphocyte function-associated antigen 1; MGD = meibomian gland dysfunction

\* Potential variations within the disease spectrum are acknowledged to exist between patients and the management options listed above are not intended to be exclusive. The severity and etiology of the DED state will dictate the range and number of management options selected from one or more steps.

† One or more options concurrently within each category can be considered within that step of the dry eye disease state. Options within a category are not ranked according to importance and may be equally valid.

‡ It should be noted that the evidence available to support the various management options differs and will inevitably be lower for newer management options. Thus, each treatment option should be considered in accordance with the level of evidence available at the time management is instigated.

§ The use of prescription drugs needs to be considered in the context of the individual patient presentation, and the relative level of evidence supporting their use for that specific indications, as this group of agents differs widely in mechanism of action.

## Mild Dry Eye

Because of the inconsistent correlation between reported symptoms and clinical signs<sup>98</sup> as well as the relatively poor specificity and/or sensitivity of clinical tests,<sup>101,102</sup> patients with suggestive symptoms without signs should be placed on trial treatments with artificial tears when other potential causes of ocular irritation have been eliminated. For patients with a clinical diagnosis of mild dry eye, potentially exacerbating exogenous factors such as antihistamine or diuretic use, cigarette smoking and exposure to second-hand smoke, environmental factors such as air drafts (e.g., use of ceiling fans), and low-humidity environments should be addressed. Cigarette smoking has been found to be associated with dry eye because of the adverse effects on the lipid layer of the precorneal tear film and tear proteins.<sup>103,104</sup> Humidifying ambient air and avoiding air drafts by using side shields on spectacles and by changing the characteristics of airflow at work, at home, and in the car may be helpful. Measures such as lowering the computer screen to below eye level to decrease lid aperture,<sup>105</sup> scheduling regular breaks, and increasing efforts to consciously blink may decrease the discomfort associated with computer and reading activities.

As the severity of the dry eye increases, aqueous enhancement of the eye using topical agents is appropriate. Emulsions, gels, and ointments can be used. The use of artificial tears may be increased, but the practicality of frequent tear instillation depends on the lifestyle or manual dexterity of the patient. Nonpreserved tear substitutes are generally preferable; however, tears with preservatives may be sufficient for patients with mild dry eye and an otherwise healthy ocular surface. When tear substitutes are used frequently and chronically (e.g., more than four times a day), nonpreserved tear substitutes are generally recommended. A recent systematic literature review found that artificial tears are safe and an effective modality for treating dry eye.<sup>106</sup> [I+, Good, Strong] The literature indicated that the most artificial tears may have comparable efficacies. Although, the authors cautioned that there were significant inconsistencies in study designs and reporting trial results.

Contributing ocular factors such as blepharitis or meibomianitis should also be treated (see Blepharitis PPP<sup>107</sup>). Eyelid abnormalities resulting from blepharitis,<sup>107</sup> trichiasis, or lid malposition (e.g., lagophthalmos, entropion/ectropion) should be corrected.

## Moderate Dry Eye

In addition to the treatments for mild dry eye, the following medications, surgical procedures, and other treatments may be helpful for moderate dry eye.

Anti-inflammatory therapies may be considered in addition to aqueous enhancement therapies. Cyclosporine is a fungus-derived peptide that prevents activation and nuclear translocation of cytoplasmic transcription factors that are required for T-cell activation and inflammatory cytokine production. It also inhibits mitochondrial pathways of apoptosis. In clinical trials submitted for FDA approval, topical cyclosporine 0.05% demonstrated a statistically significant 10-mm increase in Schirmer test results compared with vehicle at 6 months for those patients whose tear production was presumed to be decreased because of ocular inflammation. This effect was noted in 15% of cyclosporine-treated patients compared with 5% of vehicle-treated patients. While the drop is typically well tolerated, ocular burning was reported in 17% of the patients.<sup>108</sup> A subsequent small study demonstrated the efficacy of cyclosporine 0.05% in the treatment of dry eye in patients who had undergone punctal occlusion.<sup>109</sup> A recent study evaluated the efficacy of topical cyclosporine 0.05% in patients with mild, moderate, and severe dry eyes. They demonstrated success in 74%, 72%, and 67% of patients, respectively.<sup>110</sup> The dose can be decreased to once a day in a portion of the patients after 1 full year of twice-daily therapy without a decrease in beneficial effects.<sup>111</sup>

A retrospective, small-scale, clinical study reported prolonged improvement of dry eye signs but not symptoms after a median 23 (7–51) months of topical cyclosporine lasting for a median of 20 (8–41) months.<sup>5,6</sup> A recent systematic review of relevant published papers revealed that topical 0.05% cyclosporine eyedrops twice daily significantly improved both the objective and subjective outcomes in dry eye patients. Topical cyclosporine might be a disease-modifying agent for dry eye disease.

The exact mechanism of action of lifitegrast in the treatment of dry eye disease is unknown. It is theorized that the mechanism involves blocking the interaction between lymphocyte function-associated antigen 1 (LFA-1) and its ligand intracellular adhesion molecule 1 (ICAM-1); ICAM-1, which is upregulated in dry eye,<sup>112</sup> binds to LFA-1, a surface protein found on lymphocytes. This interaction contributes to the formation of an immunologic synapse that results in T-cell activation and migration to target tissues. Topical lifitegrast 5% was approved by the FDA for treatment of dry eye. Published studies show benefit in signs (corneal and conjunctival staining) as well as symptoms (eye dryness score and ocular discomfort) over a period of 3 months of using lifitegrast.<sup>7-9</sup> Although, the drug seems to be safe over 12 months, long-term effects are unknown.<sup>10</sup>



Corticosteroids have been reported to decrease ocular irritation symptoms, decrease corneal fluorescein staining, and improve filamentary keratitis.<sup>113-115</sup> [I+, Good, Strong] In one study, a 2-week pretreatment of patients with a topical nonpreserved corticosteroid before punctal occlusion was reported to reduce ocular irritation symptoms and corneal fluorescein staining.<sup>116</sup> Commercially available loteprednol etabonate 0.5% was used in a prospective randomized study, and over a 2-week period of use there was a beneficial effect in patients' symptoms and conjunctival hyperemia findings but not in ocular surface staining, Schirmer test results, or use of artificial tears. Extending the treatment to 4 weeks did not show any further beneficial effects or increase in side-effect profile.<sup>113</sup> Low-dose topical corticosteroid therapy can be used at infrequent intervals for short periods of time (i.e., several weeks) to suppress ocular surface inflammation. Patients who have been prescribed corticosteroids for dry eye should be monitored for adverse effects such as increased intraocular pressure and cataract formation.

Use of essential fatty acid supplements for dry eye treatment has been reported<sup>117,118</sup> to be potentially beneficial.<sup>119,120</sup> An important obstacle in conducting high-quality trials of these supplements is the lack of standardization in the various formulations in a largely unregulated industry. A recent, large scale, masked, prospective trial did not demonstrate benefit of oral fatty acids over 12 months compared with placebo.<sup>4</sup> This study specifically examined the utility of omega-3 supplements in patients with moderate to severe dry eye. There have been other reports of some improvement in patients with blepharitis when omega-3 supplements were used as adjunctive therapy.<sup>121</sup> For patients with aqueous tear deficiency, punctal occlusion is considered when the medical means of aqueous enhancement are ineffective or impractical. Punctal plugs are best used once tear homeostasis is achieved. A Cochrane Collaboration review found limited evidence in seven randomized controlled trials that silicone plugs may provide symptomatic relief in patients with severe dry eye.<sup>122</sup> [I+, Good, Discretionary] Punctal occlusion can be accomplished with nonabsorbable materials such as silicone or thermal labile polymer plugs that are lodged at the punctal orifice in patients who will need long-term occlusion. The effectiveness of increasing the lower tear meniscus was similar with upper or lower tear duct occlusion.<sup>123</sup> Silicone plugs placed in the punctum have been shown to improve dry eye signs and symptoms, though in some patients they may irritate the conjunctival surface because of their shape.<sup>122,124-126</sup> Silicone plugs have the advantage of being removable if the patient develops symptoms of epiphora or irritation, but they may be retained for many years without complications, provided they

are appropriately sized. The largest plug that can be inserted should be used to reduce the likelihood of extrusion. One study found that 56% of silicone plugs were retained after 2 years, but in those patients whose plugs were spontaneously lost, 34% were reported to have canalicular stenosis at 2 years.<sup>127</sup> Patients who benefit from having punctal plugs in place but spontaneously lose them may have the lost plug(s) replaced or undergo permanent closure of their punctum by a thermal cautery or alternative means. Punctal plugs that are displaced into the lacrimal system may pass through the entire system, but blockage with secondary infection has been reported.<sup>128,129</sup> Surgical removal is rarely necessary. Thermal labile polymer plugs are placed intracannicularly, and they have the advantage of not irritating the ocular surface. However, they have been associated with the occurrence of epiphora, canaliculitis, dacryocystitis, and keratitis.<sup>128,130</sup> Punctal plugs should be used with caution in patients with concomitant inflammatory ocular diseases, such as rosacea conjunctivitis and/or allergic conjunctivitis, since they may exacerbate patients' symptoms.

Eyeglass side shields and moisture chambers are noninvasive therapies that can be used. These types of eyeglasses are frequently worn by motorcyclists and mountain climbers and can be purchased at stores or online. Slow-release hydroxypropyl cellulose inserts are occasionally helpful for patients who are unable to apply artificial tears.<sup>131,132</sup> Other available therapies include intranasal neurostimulation<sup>133</sup> and labial mucous membrane and minor salivary gland transplantations.<sup>134</sup>

### Severe Dry Eye

In addition to the treatments for mild and moderate dry eye, the following treatments may be considered for severe dry eye.

Oral medications are available to treat severe dry eyes, especially for patients with combined dry eye and dry mouth (Sjögren syndrome).<sup>135-137</sup> Cholinergic agonists, pilocarpine, and cevimeline have been approved by the FDA to treat the symptoms of dry mouth in patients with Sjögren syndrome. These medications bind to muscarinic receptors, which stimulate secretion of the salivary and sweat glands, and they also appear to improve tear production. Most clinical studies demonstrate greater improvement in dry mouth than dry eye.<sup>135,138</sup> Patients treated with pilocarpine at a dose of 5 mg orally four times a day experienced a significantly greater overall improvement in the ability to focus their eyes during reading and in symptoms of blurred vision compared with placebo-treated patients.<sup>135</sup> The most common side effect from this medication was excessive sweating, which occurred in over 40% of patients. Two

percent of the patients taking oral pilocarpine withdrew from the study because of this and other drug-related side effects. Cevimeline is another oral cholinergic agonist that has been found to improve ocular irritation symptoms and aqueous tear production.<sup>137</sup> This agent may have fewer adverse systemic side effects than oral pilocarpine.

Autologous serum drops have been reported to improve ocular irritation symptoms as well as conjunctival and corneal dye staining in patients with Sjögren syndrome<sup>139</sup> and GVHD.<sup>140</sup> A recent systematic review reported a benefit in symptoms with autologous serum compared with artificial tears in the short-term.<sup>141</sup> [I+, Moderate, Discretionary] For patients for whom repeated blood sampling is not possible, allogeneic serum eye drops have been shown to be an effective and safe alternative.<sup>142,143</sup>

Filamentary keratitis can be treated by debriding the filaments or applying topical mucolytic agents, such as acetylcysteine 10% four times a day. Filaments can be debrided with a moistened cotton-tip applicator, dry cellulose sponge, or jewelers' forceps. Soft contact lenses are effective in preventing recurrence of filamentary keratitis but may be poorly tolerated if the patient has severe dry eye. If the patient has associated neurotrophic keratopathy, contact lenses should be used with caution owing to risk of infection. The insertion of a self-retaining amniotic membrane in refractory cases should be considered but with recognition of the short-term effect.

Permanent punctal occlusion can be accomplished by means of thermal or laser cautery. In general, laser cautery is not as effective as thermal cautery in achieving permanent, complete occlusion, and it is more expensive. The main disadvantage of punctal cautery is that it is not readily reversible. If occlusion with cautery is planned, a trial occlusion with nonpermanent implants generally should be performed first to screen for the potential development of epiphora. Silicone punctal plugs are more useful for this purpose. A stepwise approach to cautery occlusion is generally recommended so that no more than one punctum is cauterized in each eye at a treatment session. A limited tarsorrhaphy can be performed to decrease tear film instability in patients with severe dry eye who have not responded to other therapies.<sup>144</sup>

Rigid gas-permeable scleral lenses have been used successfully in the treatment of severe dry eye for years.<sup>145-147</sup> Widespread use of scleral lenses<sup>148</sup> may be limited by fitting difficulties (particularly in the presence of conjunctival cicatrization), patient willingness and ability to wear the lenses, and high costs. Soft contact lenses may provide symptomatic relief in selected cases, particularly in the setting of filamentary keratitis. The use of contact lenses must be tempered by the risk of corneal infection.

## Follow-up Evaluation

The purpose of the follow-up evaluation is to assess the response to therapy as a basis for altering or adjusting treatment as necessary, to monitor for ocular surface damage, and to provide reassurance. The frequency and extent of the follow-up evaluation will depend on the severity of disease, the therapeutic approach, and the response to the therapy. For example, patients with sterile corneal ulceration associated with dry eye may require daily follow-up.

## PROVIDER AND SETTING

Because dry eye can be associated with systemic immunological disorders and the use of systemic medications, broad medical skills and training, such as found in ophthalmologists, are important for appropriate diagnosis and management. Patients with dry eye who are evaluated by non-ophthalmologist health care providers should be referred promptly to the ophthalmologist if any of the following occurs:

- ◆ Moderate or severe pain
- ◆ Lack of response to the therapy
- ◆ Corneal infiltration or ulceration
- ◆ Vision loss

## COUNSELING AND REFERRAL

The most important aspects of caring for patients with dry eye are to educate them about the chronic nature of the disease process and to provide specific instructions for therapeutic regimens. It is helpful to periodically reassess the patient's compliance and understanding of the disease, the benefits of treatment and potential complications, and to reinform the patient as necessary. The patient and physician together can establish realistic expectations for effective management.

Patients with severe dry eye are at greater risk for contact lens intolerance and associated complications. Patients who have dry eye and are considering keratorefractive surgery, particularly LASIK, should be cautioned that keratorefractive surgery may worsen their dry eye condition.<sup>149</sup> Effective treatment for dry eye should be achieved before undergoing keratorefractive surgery.<sup>150</sup> Uncontrolled dry eye disease is a contraindication for keratorefractive surgery.<sup>151</sup>

Referral of a patient with dry eye may be necessary, depending on the severity of the condition and its responsiveness to treatment. In moderate to severe cases that are unresponsive to treatment or when systemic disease is suspected, timely referral to an

ophthalmologist who is knowledgeable and experienced in the management of these entities is recommended. Referral to an internist or rheumatologist can be considered for patients with systemic immune dysfunction or for those who require immunosuppressive therapy. Patients with systemic disease such as primary Sjögren syndrome, secondary Sjögren (associated with a connective-tissue disease), or connective tissue disease such as rheumatoid arthritis should be managed by an appropriate medical specialist. Patient support groups such as the Sjögren's Syndrome Foundation ([www.sjogrens.org](http://www.sjogrens.org)) may help patients adjust to their condition. Some patients may benefit from professional counseling as an aid in coping with chronic dry eye.

## SOCIOECONOMIC CONSIDERATIONS

Dry eye is a common ocular condition that has a prevalence as high as 33% in Japan.<sup>152</sup> In the United States, two large cross-sectional surveys, the Women's Health Study and the Physician's Health Studies, demonstrated that the prevalence of physician-diagnosed dry eye or severe dry eye symptoms was 7.8% in women and 4.3% in men 50 and older.<sup>23,24</sup> Claims data from a large US managed care database (reflecting only individuals who seek medical care and are diagnosed with dry eye) suggest that the prevalence of clinically diagnosed dry eye is 0.4% to 0.5% over all ages and that it is highest among women and the elderly (65 years and older).<sup>26</sup>

A similar estimate was obtained from the Dry Eye Management Outcomes Simulation.<sup>153</sup> In this study, data from multiple sources were used to estimate medical costs and outcomes of dry eye. The prevalence in a typical managed care population was estimated at approximately 1%. Of these cases, about 60% are mild in severity, 30% moderate, and 10% severe. Of individuals with mild dry eye, only about 20% seek medical care compared with 50% of those with moderate disease and 100% of those with severe disease. This suggests that approximately 0.4% of individuals in a typical managed care population seek medical care for and are diagnosed with dry eye.

Dry eye causes considerable burden to the patient as well as the society. Studies suggest that dry eye is associated with significant impact on visual function such as reading and driving,<sup>154</sup> daily activities, social and physical functioning, workplace productivity, and quality of life.<sup>155</sup>

A study of dry eye and quality of life found decreased quality of life for all severity levels of dry eye disease, with an effect on quality of life for severe dry eye comparable with that reported for moderate angina.<sup>156</sup> One study of a cohort of dry eye patients found a strong association with anxiety and depression.<sup>157</sup> Several other studies demonstrated a relationship

between depression and dry eye symptoms (with or without dry eye signs) independent of the medications used to treat depression.<sup>158,159</sup> Other research suggests that patients with dry eye are more likely to report pain, limitations of activities of daily living, and lower quality of life.<sup>32,155,160</sup> In particular, the vision-related quality of life is significantly influenced by dry eye owing to impairment of reading ability.<sup>17-19</sup>

Although scarce, the existing data on the economics of dry eye suggest that the economic impact is substantial. Direct medical costs (e.g., office visits, prescription and over-the-counter medications, specialized eyewear, humidifiers, in-office procedures), direct nonmedical costs (e.g., patient transportation), indirect costs (e.g., lost work time and productivity, changes in type of work), and intangible costs (e.g., reduced quality of life, lost leisure time, impaired social, emotional, and physical functioning) determine the total cost of dry eye to the patient as well as to society.<sup>161,162</sup> Three survey studies found that the impact of dry eye on health care utilization is substantial, particularly in patients with Sjögren syndrome.<sup>163-165</sup> Various studies reported that dry eye in patients with Sjögren syndrome in particular interfered with work an average of 184 to 200 days per year. It also caused 2 to 5 days of absenteeism per year,<sup>163,165,166</sup> with an estimated productivity loss of more than \$5000 per patient per year.

In another study involving 2171 dry eye patients recruited from online databases, both the direct costs (i.e., ocular lubricants, cyclosporine, punctal plugs, physician visits, and nutritional supplements) and the indirect costs (i.e., productivity lost due to absenteeism) of their care were considered. The analysis estimated the average annual cost of treating a patient with dry eye at \$783 (with a range of \$757 to \$809 across sensitivity analyses) and the overall burden of such treatment to the US health care system at \$3.84 billion. From the societal perspective, the average annual cost of managing dry eye was estimated at \$11,302 per patient and \$55.4 billion for US society overall.<sup>167</sup> A study from England reported that, in 2014, over 6.4 million items were prescribed at a cost of over £27 million to the society.<sup>168</sup>

Dry eye is a chronic condition. A number of therapies, mostly palliative, have been shown to improve symptoms of dry eye. Although it seems likely that these therapies would also improve quality of life and productivity and reduce overall health care utilization, few clinical studies have assessed patient-reported outcomes (e.g., quality of life), or economic measures, particularly the cost of therapy. Long-term topical treatment for dry eye disease is costly, and in the case of tear supplements, this cost is usually not covered by an insurance plan.

# APPENDIX 1. QUALITY OF OPHTHALMIC CARE CORE CRITERIA

*Providing quality care  
is the physician's foremost ethical obligation, and is  
the basis of public trust in physicians.*

*AMA Board of Trustees, 1986*

Quality ophthalmic care is provided in a manner and with the skill that is consistent with the best interests of the patient. The discussion that follows characterizes the core elements of such care.

The ophthalmologist is first and foremost a physician. As such, the ophthalmologist demonstrates compassion and concern for the individual, and utilizes the science and art of medicine to help alleviate patient fear and suffering. The ophthalmologist strives to develop and maintain clinical skills at the highest feasible level, consistent with the needs of patients, through training and continuing education. The ophthalmologist evaluates those skills and medical knowledge in relation to the needs of the patient and responds accordingly. The ophthalmologist also ensures that needy patients receive necessary care directly or through referral to appropriate persons and facilities that will provide such care, and he or she supports activities that promote health and prevent disease and disability.

The ophthalmologist recognizes that disease places patients in a disadvantaged, dependent state. The ophthalmologist respects the dignity and integrity of his or her patients, and does not exploit their vulnerability.

Quality ophthalmic care has the following optimal attributes, among others.

- ◆ The essence of quality care is a meaningful partnership relationship between patient and physician. The ophthalmologist strives to communicate effectively with his or her patients, listening carefully to their needs and concerns. In turn, the ophthalmologist educates his or her patients about the nature and prognosis of their condition and about proper and appropriate therapeutic modalities. This is to ensure their meaningful participation (appropriate to their unique physical, intellectual and emotional state) in decisions affecting their management and care, to improve their motivation and compliance with the agreed plan of treatment, and to help alleviate their fears and concerns.
- ◆ The ophthalmologist uses his or her best judgment in choosing and timing appropriate diagnostic and therapeutic modalities as well as the frequency of evaluation and follow-up, with due regard to the urgency and nature of the patient's condition and unique needs and desires.
- ◆ The ophthalmologist carries out only those procedures for which he or she is adequately trained, experienced and competent, or, when necessary, is assisted by someone who is, depending on the urgency of the problem and availability and accessibility of alternative providers.
- ◆ Patients are assured access to, and continuity of, needed and appropriate ophthalmic care, which can be described as follows.
  - ◆ The ophthalmologist treats patients with due regard to timeliness, appropriateness, and his or her own ability to provide such care.
  - ◆ The operating ophthalmologist makes adequate provision for appropriate pre- and postoperative patient care.
  - ◆ When the ophthalmologist is unavailable for his or her patient, he or she provides appropriate alternate ophthalmic care, with adequate mechanisms for informing patients of the existence of such care and procedures for obtaining it.
  - ◆ The ophthalmologist refers patients to other ophthalmologists and eye care providers based on the timeliness and appropriateness of such referral, the patient's needs, the competence and qualifications of the person to whom the referral is made, and access and availability.
  - ◆ The ophthalmologist seeks appropriate consultation with due regard to the nature of the ocular or other medical or surgical problem. Consultants are suggested for their skill, competence, and accessibility. They receive as complete and accurate an accounting of the problem as necessary to provide efficient and effective advice or intervention, and in turn respond in an adequate and timely manner.
  - ◆ The ophthalmologist maintains complete and accurate medical records.

- ◆ On appropriate request, the ophthalmologist provides a full and accurate rendering of the patient's records in his or her possession.
- ◆ The ophthalmologist reviews the results of consultations and laboratory tests in a timely and effective manner and takes appropriate actions.
- ◆ The ophthalmologist and those who assist in providing care identify themselves and their profession.
- ◆ For patients whose conditions fail to respond to treatment and for whom further treatment is unavailable, the ophthalmologist provides proper professional support, counseling, rehabilitative and social services, and referral as appropriate and accessible.
- ◆ Prior to therapeutic or invasive diagnostic procedures, the ophthalmologist becomes appropriately conversant with the patient's condition by collecting pertinent historical information and performing relevant preoperative examinations. Additionally, he or she enables the patient to reach a fully informed decision by providing an accurate and truthful explanation of the diagnosis; the nature, purpose, risks, benefits, and probability of success of the proposed treatment and of alternative treatment; and the risks and benefits of no treatment.
- ◆ The ophthalmologist adopts new technology (e.g., drugs, devices, surgical techniques) in judicious fashion, appropriate to the cost and potential benefit relative to existing alternatives and to its demonstrated safety and efficacy.
- ◆ The ophthalmologist enhances the quality of care he or she provides by periodically reviewing and assessing his or her personal performance in relation to established standards, and by revising or altering his or her practices and techniques appropriately.
- ◆ The ophthalmologist improves ophthalmic care by communicating to colleagues, through appropriate professional channels, knowledge gained through clinical research and practice. This includes alerting colleagues of instances of unusual or unexpected rates of complications and problems related to new drugs, devices or procedures.
- ◆ The ophthalmologist provides care in suitably staffed and equipped facilities adequate to deal with potential ocular and systemic complications requiring immediate attention.
- ◆ The ophthalmologist also provides ophthalmic care in a manner that is cost effective without unacceptably compromising accepted standards of quality.

Reviewed by: Council  
Approved by: Board of Trustees  
October 12, 1988

2<sup>nd</sup> Printing: January 1991

3<sup>rd</sup> Printing: August 2001

4<sup>th</sup> Printing: July 2005



## APPENDIX 2. INTERNATIONAL STATISTICAL CLASSIFICATION OF DISEASES AND RELATED HEALTH PROBLEMS (ICD) CODES

Dry eye includes entities with the following ICD-10 classifications:

	ICD-10 CM
Dry eye, unspecified, right lacrimal gland	H04.121
Dry eye, unspecified, left lacrimal gland	H04.122
Dry eye, unspecified, bilateral lacrimal gland	H04.123
Dry eye, keratoconjunctivitis sicca (not specified as Sjögren)	H16.22-
Dry eye, Sjögren syndrome, Sicca syndrome	M35.00
Dry eye, Sjögren syndrome, with keratoconjunctivitis	M35.01

CM = Clinical Modification used in the United States; ICD = International Classification of Diseases; (-) = 1, right eye; 2, left eye; 3, bilateral

Additional information:

- Certain ICD-10 CM categories have applicable 7<sup>th</sup> characters. The applicable 7<sup>th</sup> character is required for all codes within the category, or as the notes in the Tabular List instruct. The 7<sup>th</sup> character must always be the 7<sup>th</sup> character in the data field. If a code that requires a 7<sup>th</sup> character is not 6 characters, a placeholder X must be used to fill in the empty characters.
- For bilateral sites, the final character of the codes in the ICD-10 CM indicates laterality. If no bilateral code is provided and the condition is bilateral, separate codes for both the left and right side should be assigned. Unspecified codes should only be used when there is no other code option available.
- When the diagnosis code specifies laterality, regardless of which digit it is found in (i.e., 4<sup>th</sup> digit, 5<sup>th</sup> digit, or 6<sup>th</sup> digit):
  - Right is always 1
  - Left is always 2
  - Bilateral is always 3

## APPENDIX 3. SJÖGREN SYNDROME

Sjögren syndrome is defined as dry eye and dry mouth associated with systemic immune dysfunction. About 10% of patients with clinically significant dry eye have an underlying Sjögren syndrome.<sup>57,58</sup> A significant proportion of the patients may not have been diagnosed at the time they present to the ophthalmology clinic with dry eye complaints.

Sjögren syndrome is characterized by infiltration of the lacrimal and salivary glands with lymphocytes with secondary compromise of gland function. Systemic disease and symptoms may include arthralgia, myalgia, or fatigue. Patients with primary Sjögren syndrome may also have associated thyroid dysfunction or autoimmune thyroiditis.<sup>169</sup> Patients with secondary Sjögren syndrome have a distinct autoimmune disease such as rheumatoid arthritis, scleroderma, or systemic lupus erythematosus. Patients with Sjögren syndrome, whether they have secondary autoimmune disease or not, should be comanaged with a rheumatologist owing to the many possible comorbid systemic conditions. An epidemiologic study performed in Sweden reported that the prevalence of Sjögren syndrome is approximately 0.4%.<sup>170</sup> A Greek epidemiologic study reported the annual incidence of Sjögren syndrome as 5.3 per 100,000 and a prevalence of 92.8 cases per 100,000, with a female-to-male ratio of 20:1.<sup>171</sup> Women are much more commonly diagnosed with Sjögren syndrome than men.<sup>172,173</sup> A study in Slovenia estimated the annual incidence of primary Sjögren syndrome as 3.9 per 100,000.<sup>174</sup> Sjögren syndrome should be suspected if intrinsic tear-production deficiency is detected in nonelderly women, especially if it is rapid in onset and/or marked in severity. Diagnosis and treatment of underlying systemic immune disorders may decrease morbidity and may even be lifesaving. Patients with dry eye disease associated with Sjögren syndrome may develop other ocular manifestations of immune dysfunction, including scleritis, sterile keratitis, and uveitis. Patients are also at increased risk for potentially life-threatening vasculitic or lymphoproliferative disorders. Studies have shown that patients with decreased C4 levels at the time of diagnosis of Sjögren syndrome had a higher risk of developing lymphoma.<sup>175,176</sup>

Defined, objective criteria for diagnosing and classifying Sjögren syndrome have been proposed. The latest classification criteria are based on the weighted sum of five items: anti-SSA/Ro antibody positivity and focal lymphocytic sialadenitis with a focus score of  $\geq 1$  foci/4 mm<sup>2</sup>, each scoring 3; an abnormal ocular staining score of  $\geq 5$  (or van Bijsterveld score of  $\geq 4$ ), a Schirmer's test result of  $\leq 5$  mm/5 minutes, and an unstimulated salivary flow rate of  $\leq 0.1$  ml/minute, each scoring 1. Individuals with signs and/or symptoms suggestive of Sjögren syndrome who have a total score of  $\geq 4$  for the those items meet the criteria for primary Sjögren syndrome.<sup>177,178</sup>

A panel of experts, with support from the Sjögren Syndrome Foundation, also published a set of clinical guidelines regarding management of patients with Sjögren-related dry eye as follows. "Evaluation of the patients should include symptoms of both discomfort and visual disturbance as well as determination of the relative contribution of aqueous production deficiency and evaporative loss of tear volume. Objective parameters of tear film stability, tear osmolarity, degree of lid margin disease, and ocular surface damage should be used to stage severity of dry eye disease to assist in selecting appropriate treatment options. Patient education with regard to the nature of the problem, aggravating factors, and goals of treatment is critical to successful management. Tear

supplementation and stabilization, control of inflammation of the lacrimal glands and ocular surface, and possible stimulation of tear production are treatment options that are used according to the character and severity of dry eye disease.”<sup>179</sup> An outcomes-based review of treatment options for patients with dry eye secondary to Sjögren's syndrome has recently been published.<sup>180</sup> Although there was paucity of rigorous clinical trials to support therapy recommendations, topical lubricants, topical anti-inflammatory therapy, and tear-conserving strategies seemed effective. [I+, Good, Strong] The efficacy of oral secretagogues was greater in the treatment of oral dryness than ocular dryness. Although oral hydroxychloroquine is commonly prescribed to patients with SS to alleviate fatigue and arthralgias, the literature did not demonstrate strong evidence for the efficacy of this treatment for dry eye. Another systematic review of controlled trials confirmed benefits for oral secretagogues (pilocarpine and cevimeline) for sicca features (mostly oral) and topical anti-inflammatories (cyclosporine) for moderate or severe dry eye.<sup>181</sup> [I+, Good, Strong] Anti-tumor necrosis factor agents were not found effective and the evidence for efficacy of rituximab was not strong. [I+, Good, Strong]

## APPENDIX 4. DIAGNOSTIC TESTS

This appendix summarizes the applicability of currently utilized tests to diagnose tear film and ocular surface disorders. These tests include the tear break-up time test to evaluate tear film stability, ocular surface dye staining to evaluate ocular surface disease, the Schirmer test and fluorescein disappearance test to evaluate aqueous tear production and clearance, and the tear osmolarity test.

### TEAR BREAK-UP TIME TEST

Tear break-up time is determined by instilling fluorescein dye in the inferior cul-de-sac and then evaluating the stability of the precorneal tear film.<sup>92</sup> The test is performed by moistening a fluorescein strip with sterile nonpreserved saline and applying it to the inferior tarsal conjunctiva. Fluorescein-anesthetic combination drops are not ideal for this purpose, as the anesthetic may affect the result of the test. After several blinks, the tear film is examined using a broad beam of the slit-lamp biomicroscope with a cobalt blue filter. The time lapse between the last blink and the appearance of the first randomly distributed dark discontinuity in the fluorescein-stained tear film is the tear break-up time. The tear break-up time should be evaluated before the instillation of any eye drops and before the eyelids are manipulated in any way.

Recurrent tear break-up in the same area may indicate localized anterior basement-membrane abnormalities. Break-up times less than 10 seconds are considered abnormal.<sup>92</sup> A rapid tear break-up time is observed in both aqueous tear deficiency and meibomian gland disease (MGD).<sup>92</sup>

### OCULAR SURFACE DYE STAINING

Fluorescein, rose bengal, or lissamine green dyes may be used to assess the ocular surface.

Fluorescein dye stains areas of the corneal and conjunctival epithelium where there is sufficient disruption of intercellular junctions to allow the dye to permeate into the tissue.<sup>182</sup> A saline-moistened fluorescein strip or topical instillation of a 1% to 2% sodium fluorescein solution is used to stain the tear film. After instilling the dye, the ocular surface is examined through a biomicroscope using a cobalt blue filter. Staining may become more apparent after about 2 minutes, and it is more intense when it is observed with a yellow filter. Mild fluorescein staining can be observed in normal eyes and may be more prominent in the morning. Exposure-zone punctate or blotchy fluorescein staining is observed in dry eye, and staining is more easily visualized on the cornea than on the conjunctiva.

Rose bengal staining of the tear film may be performed using a saline-moistened strip or 1% solution. (Patients should be informed that the drop might irritate the eye, and therefore, it is typical to use a topical anesthetic prior to instillation.) The saline drop used to moisten the strip should remain in contact with the strip for at least a minute to achieve an adequate concentration of rose bengal to stain the ocular surface. Rose bengal staining is more intense on the conjunctiva than on the cornea. The dye stains ocular surface cells that lack a mucous coating as well as debris in the tear film;<sup>182</sup> the staining may be easier to observe with a red-free filter.

When using lissamine green dye, waiting 1 to 2 minutes lessens the ability to see the staining pattern. It is different from fluorescein, which requires about 2 minutes to highlight the punctate erosions. The lissamine green dye has a staining profile similar to that of rose bengal dye,<sup>183-185</sup> but it causes less ocular irritation.<sup>184,185</sup> It is not recommended for evaluating corneal epithelial disease. Diffuse corneal and conjunctival staining is commonly seen in viral keratoconjunctivitis and medicamentosa. Staining of the inferior cornea and bulbar conjunctiva is typically observed in patients with staphylococcal blepharitis, MGD, lagophthalmos, and exposure, whereas staining of the superior bulbar conjunctiva is typically seen in superior limbic keratoconjunctivitis. A pattern of exposure-zone (interpalpebral) corneal and bulbar conjunctival staining is typically seen with aqueous tear deficiency.<sup>186,187</sup>

Corneal sensation is tested prior to any drops being placed in the eye, especially topical anesthetics. Using a cotton tip applicator with the tip twisted to bring the cotton fibers to a point, it can be used to test sensation. Normal sensation is any touching of the cotton fibers that causes sensation. Neurotrophic keratopathy can be grossly graded by the amount of the cotton tip needed to cause a sensation. Historically, the Cochet-Bonnet aesthesiometer is a device which tests corneal sensation quantitatively by using a nylon filament that can be retracted, creating a stiffer and stiffer filament. The lower the number, the less of the fiber is exposed, indicating decreased corneal sensation.

## SCHIRMER TEST

The Schirmer test can be performed to evaluate aqueous tear production, but it is well recognized that it gives variable results and should not be used as the sole criterion for diagnosing dry eye. It is performed by placing a narrow filter-paper strip in the inferior cul-de-sac. Aqueous tear production is measured by the length in millimeters that the strip wets during the test period, generally 5 minutes.<sup>187</sup> Schirmer testing may be performed with or without the use of topical anesthesia. The Schirmer test with anesthesia, also referred to as a basic secretion test, has been reported to give more variable results than the Schirmer test done without anesthesia.<sup>102</sup> Results of 10 mm or less for the Schirmer test with anesthesia are generally considered abnormal.<sup>94,95</sup> A Schirmer basal secretion score of 5 to 10 mm is relatively insignificant.<sup>188</sup> If topical anesthesia is applied, excess fluid should be gently removed from the cul-de-sac prior to insertion of the filter paper. Although no absolute cutoff has been established for this test, less than 10 mm of strip wetting in 5 minutes is suggestive of abnormality in patients tested without anesthesia.<sup>92</sup> While an isolated abnormal result can be nonspecific, serially consistent low results are strongly suggestive of aqueous tear deficiency.

## FLUORESCEIN DYE DISAPPEARANCE TEST/TEAR FUNCTION INDEX

The clearance or turnover of tears on the ocular surface can be assessed using a number of tests, including the fluorescein disappearance test and tear function index.<sup>96,189</sup> These tests are performed by instilling a measured amount of fluorescein dye on to the ocular surface, then assessing clearance of the dye by visually comparing the residual dye in the inferior tear meniscus to the Schirmer strip that has been placed onto the ocular surface with a standard color scale.<sup>96,189</sup> This test assesses aqueous

tear production, tear volume, and tear drainage. It has been found to show better correlation with the severity of ocular irritation symptoms and corneal fluorescein staining than the Schirmer test.<sup>190,191</sup>

## TEAR OSMOLARITY TEST

Tear osmolality has long been thought to be a key feature of dry eye.<sup>192-194</sup> However, the test did not gain popularity until after the Food and Drug Administration (FDA) clearance of a commercially available device (TearLab, San Diego, CA) in 2009 to be used as a point-of-care laboratory test to diagnose dry eye. Since then a number of studies have been published reporting on the utility of this device. A current review of the literature demonstrates conflicting results. There are a number of studies published by independent researchers suggesting that osmolality exhibits the strongest correlation with disease severity of any single objective metric in clinical use<sup>86,195-198</sup> and predicts response to therapeutic interventions.<sup>199-201</sup> At the same time, tear osmolality has also been criticized by others for its lack of correlation to symptoms and to the other objective dry eye signs.<sup>89,202</sup>

At a cutoff of 312 mOsm/L, tear hyperosmolality is noted to have 73% sensitivity and 92% specificity for diagnosing dry eye.<sup>86</sup> By contrast, the other clinical tests commonly used in diagnosing dry eye have either poorer sensitivity (corneal staining, 54%; conjunctival staining, 60%; meibomian gland grading, 61%) or specificity (tear film break-up time, 45%; Schirmer test, 51%). However, these numbers, in isolation, are not particularly helpful and should be considered within the context of symptoms and other clinical findings. Rather than relying solely on an absolute number obtained via one-time measurement, correlation with clinical findings or differences in osmolality over time or under different conditions would seem to be more important to confirm the diagnosis of dry eye. Indeed, most recent studies confirm that normal subjects have exceptionally stable tear film osmolality, whereas tear osmolality values in dry eye subjects become unstable quickly and lose homeostasis with environmental changes.<sup>85</sup>

A recent, large-scale, prospective clinical study indicated that individuals with dry eye symptoms but no significant ocular surface or tear film abnormalities seem to have higher and more variable osmolality measurements than controls, potentially indicating that changes in osmolality precede clinical findings.<sup>203</sup> Taking multiple measurements over time is required to diagnose dry eye in patients with milder disease.<sup>85</sup>

Another benefit of osmolality testing is that in the hands of a rheumatologist or general practitioner, unable to do a comprehensive external or slit-lamp examination, it may be of benefit to diagnose dry eye. More research and experience with this measurement device will help determine its value and clinical relevance.

# LITERATURE SEARCHES FOR THIS PPP

Literature searches of the PubMed and Cochrane databases were conducted in March 2017; the search strategies were as follows. Specific limited update searches were conducted after June 2018.

## **Dry Eye Syndrome:**

("dry eye syndromes"[MeSH Terms] OR dry eye[tiab])

## **Epidemiology:**

("dry eye syndromes/epidemiology"[majr:noexp]) OR ("dry eye syndromes/ethnology"[majr:noexp]) OR ((dry eye[tiab] AND (prevalence[tiab] OR epidemiolog\*[tiab] OR ethn\*[tiab]))

## **Etiology:**

("dry eye syndromes/etiology"[majr:noexp]) OR (dry eye[tiab] AND etiolog\*[tiab])

## **Risk Factors:**

("dry eye syndromes"[majr:noexp] OR dry eye[tiab]) AND ("risk factors"[MeSH Terms] OR risk factor\*[tiab])

## **Quality of Life:**

(dry eye syndromes[majr:noexp] OR ((dry eye[tiab] AND ("quality of life"[MeSH Terms] OR "quality of life"[tiab])))

## **Cost of Illness:**

("dry eye syndromes"[majr:noexp] OR dry eye[tiab]) AND ("cost of illness"[MeSH Terms] OR "cost benefit analysis"[MeSH Terms] OR cost\*[tiab])

## **Economics:**

("dry eye syndromes/economics"[mh:noexp]) OR (dry eye[tiab] AND economic\*[tiab])

## **Therapy:**

("dry eye syndromes/drug therapy"[majr:noexp] OR "dry eye syndromes/diet therapy"[majr:noexp] OR "dry eye syndromes/surgery"[majr:noexp] OR "dry eye syndromes/therapy"[majr:noexp])

## **Pathology, Physiology:**

((("dry eye syndromes/pathology"[MAJR:noexp]) OR ("dry eye syndromes/physiology"[MAJR:noexp]) OR ("dry eye syndromes/physiopathology"[MAJR:noexp]))

**Disease Progression:**

("dry eye syndromes"[Mh:noexp] OR dry eye[tiab]) AND ("disease progression"[MeSH Terms] OR disease progress\*[tiab])

**Diagnosis:**

("dry eye syndromes/diagnosis"[MAJR:noexp])

**Prevention and Control:**

("dry eye syndromes/prevention and control"[MAJR])



# RELATED ACADEMY MATERIALS

## **Basic and Clinical Science Course**

External Disease and Cornea (Section 8, 2018–2019)

## **Patient Education Brochure**

Dry Eye (2014)

Spanish Language Brochure: Ojo Seco (2014)

## **Preferred Practice Pattern® Guidelines – Free download available at [www.aao.org/ppp](http://www.aao.org/ppp).**

Comprehensive Adult Medical Eye Evaluation (2015)

Pediatric Eye Evaluations (2017)

## REFERENCES

1. Scottish Intercollegiate Guidelines Network (SIGN). *SIGN 50: a guideline developer's handbook*. Edinburgh: SIGN; 2015. (SIGN publication no. 50). [November 2015]. Available from URL: <http://www.sign.ac.uk>.
2. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ*. 2008;336(7650):924-926.
3. GRADE Working Group. Organizations that have endorsed or that are using GRADE. <http://www.gradeworkinggroup.org/>. Accessed June 19, 2018.
4. The Dry Eye Assessment and Management Study Research Group. n-3 Fatty acid supplementation for the treatment of dry eye disease. *N Engl J Med*. 2018;378(18):1681-1690.
5. Straub M, Bron AM, Muselier-Mathieu A, Creuzot-Garcher C. Long-term outcome after topical ciclosporin in severe dry eye disease with a 10-year follow-up. *Br J Ophthalmol*. 2016;100(11):1547-1550.
6. Wilson SE, Perry HD. Long-term resolution of chronic dry eye symptoms and signs after topical cyclosporine treatment. *Ophthalmology*. 2007;114(1):76-79.
7. Sheppard JD, Torkildsen GL, Lonsdale JD, et al. Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study. *Ophthalmology*. 2014;121(2):475-483.
8. Holland EJ, Luchs J, Karpecki PM, et al. Lifitegrast for the treatment of dry eye disease: results of a phase III, randomized, double-masked, placebo-controlled trial (OPUS-3). *Ophthalmology*. 2017;124(1):53-60.
9. Tauber J, Karpecki P, Latkany R, et al. OPUS-2 Investigators. Lifitegrast ophthalmic solution 5.0% versus placebo for treatment of dry eye disease: results of the randomized phase III OPUS-2 study. *Ophthalmology*. 2015;122(12):2423-2431.
10. Donnenfeld ED, Karpecki PM, Majmudar PA, et al. Safety of lifitegrast ophthalmic solution 5.0% in patients with dry eye disease: a 1-year, multicenter, randomized, placebo-controlled study. *Cornea*. 2016;35(6):741-748.
11. Woodward MA, Randleman JB, Stulting RD. Dissatisfaction after multifocal intraocular lens implantation. *J Cataract Refract Surg*. 2009;35(6):992-997.
12. Iglesias E, Sajani R, Levitt RC, Sarantopoulos CD, Galor A. Epidemiology of Persistent Dry Eye-Like Symptoms After Cataract Surgery. *Cornea*. 2018;37(7):893-898.
13. Choi YJ, Park SY, Jun I, et al. Perioperative Ocular Parameters Associated With Persistent Dry Eye Symptoms After Cataract Surgery. *Cornea*. 2018;37(6):734-739.
14. Zintzaras E, Voulgarelis M, Moutsopoulos HM. The risk of lymphoma development in autoimmune diseases: a meta-analysis. *Arch Intern Med*. 2005;165(20):2337-2344.
15. Schein OD, Munoz B, Tielsch JM, Bandeen-Roche K, West S. Prevalence of dry eye among the elderly. *Am J Ophthalmol*. 1997;124(6):723-728.
16. Karakus SM, P.; Agrawal, D; Heinrich, C.; Ramulu, PY; Akpek, EH. Impact of Dry Eye on Prolonged Reading. *Optometry and Vision Science*. In Press.
17. Mathews PM, Ramulu PY, Swenor BS, Utine CA, Rubin GS, Akpek EK. Functional impairment of reading in patients with dry eye. *Br J Ophthalmol*. 2017;101(4):481-486.
18. Sun MJ, Rubin GS, Akpek EK, Ramulu PY. Impact of Glaucoma and Dry Eye on Text-Based Searching. *Transl Vis Sci Technol*. 2017;6(3):24.
19. van Landingham SW, West SK, Akpek EK, Munoz B, Ramulu PY. Impact of dry eye on reading in a population-based sample of the elderly: the Salisbury Eye Evaluation. *Br J Ophthalmol*. 2014;98(5):639-644.
20. Hikichi T, Yoshida A, Fukui Y, et al. Prevalence of dry eye in Japanese eye centers. *Graefes Arch Clin Exp Ophthalmol*. 1995;233(9):555-558.
21. McCarty CA, Bansal AK, Livingston PM, Stanislavsky YL, Taylor HR. The epidemiology of dry eye in Melbourne, Australia. *Ophthalmology*. 1998;105(6):1114-1119.
22. Moss SE, Klein R, Klein BE. Prevalence of and risk factors for dry eye syndrome. *Arch Ophthalmol*. 2000;118(9):1264-1268.
23. Schaumberg DA, Dana R, Buring JE, Sullivan DA. Prevalence of dry eye disease among US men: estimates from the Physicians' Health Studies. *Arch Ophthalmol*. 2009;127(6):763-768.
24. Schaumberg DA, Sullivan DA, Buring JE, Dana MR. Prevalence of dry eye syndrome among US women. *Am J Ophthalmol*. 2003;136(2):318-326.
25. Lemp MA, Crews LA, Bron AJ, Foulks GN, Sullivan BD. Distribution of aqueous-deficient and evaporative dry eye in a clinic-based patient cohort: a retrospective study. *Cornea*. 2012;31(5):472-478.

26. Yazdani C, McLaughlin T, Smeeding JE, Walt J. Prevalence of treated dry eye disease in a managed care population. *Clin Ther.* 2001;23(10):1672-1682.
27. Viso E, Rodriguez-Ares MT, Gude F. Prevalence of and associated factors for dry eye in a Spanish adult population (the Salnes Eye Study). *Ophthalmic Epidemiol.* 2009;16(1):15-21.
28. Xu L, You QS, Wang YX, Jonas JB. Associations between gender, ocular parameters and diseases: The Beijing Eye Study. *Ophthalmic Res.* 2010;45(4):197-203.
29. Moss SE, Klein R, Klein BE. Long-term incidence of dry eye in an older population. *Optom Vis Sci.* 2008;85(8):668-674.
30. Uchino M, Schaumberg DA, Dogru M, et al. Prevalence of dry eye disease among Japanese visual display terminal users. *Ophthalmology.* 2008;115(11):1982-1988.
31. Leung EW, Medeiros FA, Weinreb RN. Prevalence of ocular surface disease in glaucoma patients. *J Glaucoma.* 2008;17(5):350-355.
32. Rossi GC, Tinelli C, Pasinetti GM, Milano G, Bianchi PE. Dry eye syndrome-related quality of life in glaucoma patients. *Eur J Ophthalmol.* 2009;19(4):572-579.
33. Schaumberg DA, Buring JE, Sullivan DA, Dana MR. Hormone replacement therapy and dry eye syndrome. *JAMA.* 2001;286(17):2114-2119.
34. Ababneh OH, Cetinkaya A, Kulwin DR. Long-term efficacy and safety of botulinum toxin a injections to treat blepharospasm and hemifacial spasm. *Clin Experiment Ophthalmol.* 2014(42):254-261.
35. Ozgur OK, Murariu D, Parsa AA, Parsa FD. Dry eye syndrome due to botulinum toxin type-A injection: guideline for prevention. *Hawaii J Med Public Health.* 2012;71(5):120-123.
36. Manfredi M, Scoditti U, Angelini M, et al. Dry mouth as an initial sign of food-borne botulism: a case report and review of the literature. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod.* 2011;111(4):e15-18.
37. Zou X, Lu L, Xu Y, et al. Prevalence and clinical characteristics of dry eye disease in community-based type 2 diabetic patients: the Beixinjing eye study. *BMC Ophthalmol.* 2018;18(1):117.
38. Stern ME, Beuerman RW, Fox RI, Gao J, Mircheff AK, Pflugfelder SC. The pathology of dry eye: the interaction between the ocular surface and lacrimal glands. *Cornea.* 1998;17(6):584-589.
39. Bacmar S, Berra A, Sterin-Borda L, Borda E. Muscarinic acetylcholine receptor antibodies as a new marker of dry eye Sjogren syndrome. *Invest Ophthalmol Vis Sci.* 2001;42(2):321-327.
40. Solomon A, Dursun D, Liu Z, Xie Y, Macri A, Pflugfelder SC. Pro- and anti-inflammatory forms of interleukin-1 in the tear fluid and conjunctiva of patients with dry-eye disease. *Invest Ophthalmol Vis Sci.* 2001;42(10):2283-2292.
41. Kunert KS, Tisdale AS, Stern ME, Smith JA, Gipson IK. Analysis of topical cyclosporine treatment of patients with dry eye syndrome: effect on conjunctival lymphocytes. *Arch Ophthalmol.* 2000;118(11):1489-1496.
42. Pflugfelder SC, Solomon A, Stern ME. The diagnosis and management of dry eye: a twenty-five-year review. *Cornea.* 2000;19(5):644-649.
43. Pflugfelder SC. Antiinflammatory therapy for dry eye. *Am J Ophthalmol.* 2004;137(2):337-342.
44. Seedor JA, Lamberts D, Bergmann RB, Perry HD. Filamentary keratitis associated with diphenhydramine hydrochloride (Benadryl). *Am J Ophthalmol.* 1986;101(3):376-377.
45. Mader TH, Stulting RD. Keratoconjunctivitis sicca caused by diphenoxylate hydrochloride with atropine sulfate (Lomotil). *Am J Ophthalmol.* 1991;111(3):377-378.
46. Bergmann MT, Newman BL, Johnson NC, Jr. The effect of a diuretic (hydrochlorothiazide) on tear production in humans. *Am J Ophthalmol.* 1985;99(4):473-475.
47. Cumurcu T, Sezer E, Kilic R, Bulut Y. Comparison of dose-related ocular side effects during systemic isotretinoin administration. *Eur J Ophthalmol.* 2009;19(2):196-200.
48. Browning DJ, Rosenwasser G, Lugo M. Ocular rosacea in blacks. *Am J Ophthalmol.* 1986;101(4):441-444.
49. Kellen R, Silverberg NB. Pediatric rosacea. *Cutis.* 2016;98(1):49-53.
50. American Academy of Ophthalmology Cornea/External Disease Panel. Preferred Practice Pattern® Guidelines. Blepharitis. San Francisco, CA: American Academy of Ophthalmology; 2018. [www.aao.org/ppp](http://www.aao.org/ppp).
51. Berg M, Liden S. An epidemiological study of rosacea. *Acta Derm Venereol.* 1989;69(5):419-423.
52. Chalmers DA. Rosacea: recognition and management for the primary care provider. *Nurse Pract.* 1997;22(10):18, 23-18, 30.
53. Viswalingam M, Rauz S, Morlet N, Dart JK. Blepharokeratoconjunctivitis in children: diagnosis and treatment. *Br J Ophthalmol.* 2005;89(4):400-403.
54. Cetinkaya A, Akova YA. Pediatric ocular acne rosacea: long-term treatment with systemic antibiotics. *Am J Ophthalmol.* 2006;142(5):816-821.

55. Donaldson KE, Karp CL, Dunbar MT. Evaluation and treatment of children with ocular rosacea. *Cornea*. 2007;26(1):42-46.
56. Bamford JT, Gessert CE, Renier CM, et al. Childhood sty and adult rosacea. *J Am Acad Dermatol*. 2006;55(6):951-955.
57. Akpek EK, Klimava A, Thorne JE, Martin D, Lekhanont K, Ostrovsky A. Evaluation of patients with dry eye for presence of underlying Sjogren syndrome. *Cornea*. 2009;28(5):493-497.
58. Liew MS, Zhang M, Kim E, Akpek EK. Prevalence and predictors of Sjogren's syndrome in a prospective cohort of patients with aqueous-deficient dry eye. *Br J Ophthalmol*. 2012;96(12):1498-1503.
59. Voulgarelis M, Skopouli FN. Clinical, immunologic, and molecular factors predicting lymphoma development in Sjogren's syndrome patients. *Clin Rev Allergy Immunol*. 2007;32(3):265-274.
60. Tzioufas AG, Voulgarelis M. Update on Sjogren's syndrome autoimmune epithelitis: from classification to increased neoplasias. *Best Pract Res Clin Rheumatol*. 2007;21(6):989-1010.
61. James DG. Ocular Sarcoidosis. *Br J Ophthalmol*. 1964;48:461-470.
62. Drosos AA, Constantopoulos SH, Psychos D, Stefanou D, Papadimitriou CS, Moutsopoulos HM. The forgotten cause of sicca complex; sarcoidosis. *J Rheumatol*. 1989;16(12):1548-1551.
63. Fox RI. Systemic diseases associated with dry eye. *Int Ophthalmol Clin*. 1994;34(1):71-87.
64. Merayo-Llodes J, Baltatzis S, Foster CS. Epstein-Barr virus dacryoadenitis resulting in keratoconjunctivitis sicca in a child. *Am J Ophthalmol*. 2001;132(6):922-923.
65. Itescu S. Diffuse infiltrative lymphocytosis syndrome in human immunodeficiency virus infection--a Sjogren's-like disease. *Rheum Dis Clin North Am*. 1991;17(1):99-115.
66. Lucca JA, Farris RL, Bielory L, Caputo AR. Keratoconjunctivitis sicca in male patients infected with human immunodeficiency virus type 1. *Ophthalmology*. 1990;97(8):1008-1010.
67. Abe T, Nakajima A, Matsunaga M, Sakuragi S, Komatsu M. Decreased tear lactoferrin concentration in patients with chronic hepatitis C. *Br J Ophthalmol*. 1999;83(6):684-687.
68. Siagris D, Pharmakakis N, Christofidou M, et al. Keratoconjunctivitis sicca and chronic HCV infection. *Infection*. 2002;30(4):229-233.
69. Pflugfelder SC, Roussel TJ, Culbertson WW. Primary Sjogren's syndrome after infectious mononucleosis. *JAMA*. 1987;257(8):1049-1050.
70. Whittingham S, McNeilage J, Mackay IR. Primary Sjogren's syndrome after infectious mononucleosis. *Ann Intern Med*. 1985;102(4):490-493.
71. Pflugfelder SC, Crouse CA, Monroy D, Yen M, Rowe M, Atherton SS. Epstein-Barr virus and the lacrimal gland pathology of Sjogren's syndrome. *Am J Pathol*. 1993;143(1):49-64.
72. Ogawa Y, Okamoto S, Wakui M, et al. Dry eye after haematopoietic stem cell transplantation. *Br J Ophthalmol*. 1999;83(10):1125-1130.
73. Fahnehjelm KT, Tornquist AL, Winiarski J. Dry-eye syndrome after allogeneic stem-cell transplantation in children. *Acta Ophthalmol*. 2008;86(3):253-258.
74. Ogawa Y, Kuwana M. Dry eye as a major complication associated with chronic graft-versus-host disease after hematopoietic stem cell transplantation. *Cornea*. 2003;22(7 Suppl):S19-27.
75. Auw-Haedrich C, Potsch C, Bohringer D, et al. Histological and immunohistochemical characterisation of conjunctival graft vs host disease following haematopoietic stem cell transplantation. *Graefes Arch Clin Exp Ophthalmol*. 2007;245(7):1001-1007.
76. Deuschl G, Goddemeier C. Spontaneous and reflex activity of facial muscles in dystonia, Parkinson's disease, and in normal subjects. *J Neurol Neurosurg Psychiatry*. 1998;64(3):320-324.
77. Wang MTM, Tien L, Han A, et al. Impact of blinking on ocular surface and tear film parameters. *Ocul Surf*. 2018.
78. Moon JH, Kim KW, Moon NJ. Smartphone use is a risk factor for pediatric dry eye disease according to region and age: a case control study. *BMC Ophthalmol*. 2016;16(1):188.
79. Lemp MA. Report of the National Eye Institute/Industry workshop on Clinical Trials in Dry Eyes. *CLAO J*. 1995;21(4):221-232.
80. American Academy of Ophthalmology Basic and Clinical Science Course Subcommittee. Basic and Clinical Science Course. External Disease and Cornea: Section 8, 2017-2018. San Francisco, CA: American Academy of Ophthalmology; 2017:55-56.
81. Craig JP, Nelson JD, Azar DT, et al. TFOS DEWS II Report executive summary. *Ocul Surf*. 2017;15(4):802-812.
82. Wolffsohn JS, Arita R, Chalmers R, et al. TFOS DEWS II Diagnostic methodology report. *Ocul Surf*. 2017;15(3):539-574.

83. Feder RS, Olsen TW, Prum BE, Jr., et al. Comprehensive adult medical eye evaluation Preferred Practice Pattern® guidelines. *Ophthalmology*. 2016;123(1):P209-236. [www.aaojournal.org/content/preferred-practice-pattern](http://www.aaojournal.org/content/preferred-practice-pattern) or [www.aao.org/ppp](http://www.aao.org/ppp).
84. Karakus S, Baer AN, Agrawal D, Gurakar M, Massof RW, Akpek EK. Utility of novel autoantibodies in the diagnosis of Sjögren's syndrome among patients with dry eye. *Cornea*. 2018;37(4):405-411.
85. Keech A, Senchyna M, Jones L. Impact of time between collection and collection method on human tear fluid osmolarity. *Curr Eye Res*. 2013;38(4):428-436.
86. Lemp MA, Bron AJ, Baudouin C, et al. Tear osmolarity in the diagnosis and management of dry eye disease. *Am J Ophthalmol*. 2011;151(5):792-798.
87. Sullivan BD, Whitmer D, Nichols KK, et al. An objective approach to dry eye disease severity. *Invest Ophthalmol Vis Sci*. 2010;51(12):6125-6130.
88. Massof RW, McDonnell PJ. Latent dry eye disease state variable. *Invest Ophthalmol Vis Sci*. 2012;53(4):1905-1916.
89. Messmer EM, Bulgen M, Kampik A. Hyperosmolarity of the tear film in dry eye syndrome. *Dev Ophthalmol*. 2010;45:129-138.
90. Sambursky R, Davitt WF, 3rd, Friedberg M, Tauber S. Prospective, multicenter, clinical evaluation of point-of-care matrix metalloproteinase-9 test for confirming dry eye disease. *Cornea*. 2014;33(8):812-818.
91. American Academy of Ophthalmology Cornea/External Disease Panel. Preferred Practice Pattern® Guidelines. Conjunctivitis. San Francisco, CA: American Academy of Ophthalmology; 2018. [www.aao.org/ppp](http://www.aao.org/ppp).
92. Pflugfelder SC, Tseng SC, Sanabria O, et al. Evaluation of subjective assessments and objective diagnostic tests for diagnosing tear-film disorders known to cause ocular irritation. *Cornea*. 1998;17(1):38-56.
93. Heigle TJ, Pflugfelder SC. Aqueous tear production in patients with neurotrophic keratitis. *Cornea*. 1996;15(2):135-138.
94. Tanenbaum M, McCord Jr CD. Lacrimal drainage system. In: Tasman W, Jaeger EA, eds. *Duane's Ophthalmology*. 15th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2009:chapter 13.
95. Lemp MA, Foulks GN. Diagnosis and management of dry eye disease. In: Tasman W, Jaeger EA, eds. *Duane's Ophthalmology*. 15th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2009:chapter 14.
96. Macri A, Rolando M, Pflugfelder S. A standardized visual scale for evaluation of tear fluorescein clearance. *Ophthalmology*. 2000;107(7):1338-1343.
97. Begley CG, Chalmers RL, Abetz L, et al. The relationship between habitual patient-reported symptoms and clinical signs among patients with dry eye of varying severity. *Invest Ophthalmol Vis Sci*. 2003;44(11):4753-4761.
98. Schein OD, Tielsch JM, Munoz B, Bandeen-Roche K, West S. Relation between signs and symptoms of dry eye in the elderly. A population-based perspective. *Ophthalmology*. 1997;104(9):1395-1401.
99. Chalmers RL, Begley CG. Dryness symptoms among an unselected clinical population with and without contact lens wear. *Cont Lens Anterior Eye*. 2006;29(1):25-30.
100. Chalmers RL, Begley CG, Moody K, Hickson-Curran SB. Contact Lens Dry Eye Questionnaire-8 (CLDEQ-8) and opinion of contact lens performance. *Optom Vis Sci*. 2012;89(10):1435-1442.
101. Goren MB, Goren SB. Diagnostic tests in patients with symptoms of keratoconjunctivitis sicca. *Am J Ophthalmol*. 1988;106(5):570-574.
102. Clinch TE, Benedetto DA, Felberg NT, Laibson PR. Schirmer's test. A closer look. *Arch Ophthalmol*. 1983;101(9):1383-1386.
103. Altinors DD, Akca S, Akova YA, et al. Smoking associated with damage to the lipid layer of the ocular surface. *Am J Ophthalmol*. 2006;141(6):1016-1021.
104. Grus FH, Sabuncuo P, Augustin A, Pfeiffer N. Effect of smoking on tear proteins. *Graefes Arch Clin Exp Ophthalmol*. 2002;240(11):889-892.
105. Tsubota K, Nakamori K. Effects of ocular surface area and blink rate on tear dynamics. *Arch Ophthalmol*. 1995;113(2):155-158.
106. Pucker AD, Ng SM, Nichols JJ. Over the counter (OTC) artificial tear drops for dry eye syndrome. *Cochrane Database Syst Rev*. 2016;2:CD009729.
107. Terry MA, Ousley PJ. Deep lamellar endothelial keratoplasty in the first United States patients: early clinical results. *Cornea*. 2001;20(3):239-243.
108. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Restasis™ (cyclosporine ophthalmic emulsion) 0.05% sterile, preservative-free. NDA 50-790/S-001. 2003:6. [www.accessdata.fda.gov/drugsatfda\\_docs/label/2003/50790slr001\\_restasis\\_lbl.pdf](http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/50790slr001_restasis_lbl.pdf). Accessed June 13, 2018.

109. Roberts CW, Carniglia PE, Brazzo BG. Comparison of topical cyclosporine, punctal occlusion, and a combination for the treatment of dry eye. *Cornea*. 2007;26(7):805-809.
110. Perry HD, Solomon R, Donnenfeld ED, et al. Evaluation of topical cyclosporine for the treatment of dry eye disease. *Arch Ophthalmol*. 2008;126(8):1046-1050.
111. Su MY, Perry HD, Barsam A, et al. The effect of decreasing the dosage of cyclosporine A 0.05% on dry eye disease after 1 year of twice-daily therapy. *Cornea*. 2011;30(10):1098-1104.
112. Stern ME, Gao J, Schwalb TA, et al. Conjunctival T-cell subpopulations in Sjogren's and non-Sjogren's patients with dry eye. *Invest Ophthalmol Vis Sci*. 2002;43(8):2609-2614.
113. Pflugfelder SC, Maskin SL, Anderson B, et al. A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance. *Am J Ophthalmol*. 2004;138(3):444-457.
114. Marsh P, Pflugfelder SC. Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjogren syndrome. *Ophthalmology*. 1999;106(4):811-816.
115. Prabhasawat P, Tseng SC. Frequent association of delayed tear clearance in ocular irritation. *Br J Ophthalmol*. 1998;82(6):666-675.
116. Sainz De La Maza Serra M, Simon Castellvi C, Kabbani O. Nonpreserved topical steroids and lacrimal punctal occlusion for severe keratoconjunctivitis sicca [in Spanish]. *Arch Soc Esp Oftalmol*. 2000;75(11):751-756.
117. Wojtowicz JC, Butovich I, Uchiyama E, Aronowicz J, Agee S, McCulley JP. Pilot, prospective, randomized, double-masked, placebo-controlled clinical trial of an omega-3 supplement for dry eye. *Cornea*. 2011;30(3):308-314.
118. Jackson MA, Burrell K, Gaddie IB, Richardson SD. Efficacy of a new prescription-only medical food supplement in alleviating signs and symptoms of dry eye, with or without concomitant cyclosporine A. *Clin Ophthalmol*. 2011;5:1201-1206.
119. Perez VL, Pflugfelder SC, Zhang S, Shojaei A, Haque R. Lifitegrast, a novel integrin antagonist for treatment of dry eye disease. *Ocul Surf*. 2016;14(2):207-215.
120. Lee SY, Tong L. Lipid-containing lubricants for dry eye: a systematic review. *Optom Vis Sci*. 2012;89(11):1654-1661.
121. Macsai MS. The role of omega-3 dietary supplementation in blepharitis and meibomian gland dysfunction (an AOS thesis). *Trans Am Ophthalmol Soc*. 2008;106:336-356.
122. Ervin AM, Wojciechowski R, Schein O. Punctal occlusion for dry eye syndrome. Cochrane Database Syst Rev 2010, Issue 9. Art. No.: CD006775. DOI: 10.1002/14651858.CD006775.pub2.
123. Chen F, Wang J, Chen W, Shen M, Xu S, Lu F. Upper punctal occlusion versus lower punctal occlusion in dry eye. *Invest Ophthalmol Vis Sci*. 2010;51(11):5571-5577.
124. Altan-Yaycioglu R, Gencoglu EA, Akova YA, Dursun D, Cengiz F, Akman A. Silicone versus collagen plugs for treating dry eye: results of a prospective randomized trial including lacrimal scintigraphy. *Am J Ophthalmol*. 2005;140(1):88-93.
125. Nava-Castaneda A, Tovilla-Canales JL, Rodriguez L, Tovilla YPJL, Jones CE. Effects of lacrimal occlusion with collagen and silicone plugs on patients with conjunctivitis associated with dry eye. *Cornea*. 2003;22(1):10-14.
126. Tai MC, Cosar CB, Cohen EJ, Rapuano CJ, Laibson PR. The clinical efficacy of silicone punctal plug therapy. *Cornea*. 2002;21(2):135-139.
127. Horwath-Winter J, Thaci A, Gruber A, Boldin I. Long-term retention rates and complications of silicone punctal plugs in dry eye. *Am J Ophthalmol*. 2007;144(3):441-444.
128. Mazow ML, McCall T, Prager TC. Lodged intracanalicular plugs as a cause of lacrimal obstruction. *Ophthal Plast Reconstr Surg*. 2007;23(2):138-142.
129. SmartPlug Study Group. Management of complications after insertion of the SmartPlug punctal plug: a study of 28 patients. *Ophthalmology*. 2006;113(10):1859.
130. Feder RS, Rao RR, Lissner GS, Bryar PJ, Szatkowski M. Atypical mycobacterial keratitis and canaliculitis in a patient with an indwelling SmartPLUG. *Br J Ophthalmol*. 2010;94(3):383-384.
131. Koffler BH, McDonald M, Nelinson DS. Improved signs, symptoms, and quality of life associated with dry eye syndrome: hydroxypropyl cellulose ophthalmic insert patient registry. *Eye Contact Lens*. 2010;36(3):170-176.
132. Luchs JI, Nelinson DS, Macy JI. Efficacy of hydroxypropyl cellulose ophthalmic inserts (LACRISERT) in subsets of patients with dry eye syndrome: findings from a patient registry. *Cornea*. 2010;29(12):1417-1427.

133. Gumus K, Pflugfelder SC. Intranasal tear neurostimulation: an emerging concept in the treatment of dry eye. *Int Ophthalmol Clin*. 2017;57(2):101-108.
134. Geerling G, Raus P, Murube J. Minor salivary gland transplantation. *Dev Ophthalmol*. 2008;41:243-254.
135. Vivino FB, Al-Hashimi I, Khan Z, et al. Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjogren syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial. P92-01 Study Group. *Arch Intern Med*. 1999;159(2):174-181.
136. Fox RI, Konttinen Y, Fisher A. Use of muscarinic agonists in the treatment of Sjogren's syndrome. *Clin Immunol*. 2001;101(3):249-263.
137. Petrone D, Condemi JJ, Fife R, Gluck O, Cohen S, Dalgin P. A double-blind, randomized, placebo-controlled study of cevimeline in Sjogren's syndrome patients with xerostomia and keratoconjunctivitis sicca. *Arthritis Rheum*. 2002;46(3):748-754.
138. Nelson JD, Friedlaender M, Yeatts RP, et al. Oral pilocarpine for symptomatic relief of keratoconjunctivitis sicca in patients with Sjogren's syndrome. The MGI PHARMA Sjogren's Syndrome Study Group. *Adv Exp Med Biol*. 1998;438:979-983.
139. Tsubota K, Goto E, Fujita H, et al. Treatment of dry eye by autologous serum application in Sjogren's syndrome. *Br J Ophthalmol*. 1999;83(4):390-395.
140. Chiang CC, Lin JM, Chen WL, Tsai YY. Allogeneic serum eye drops for the treatment of severe dry eye in patients with chronic graft-versus-host disease. *Cornea*. 2007;26(7):861-863.
141. Pan Q, Angelina A, Marrone M, Stark WJ, Akpek EK. Autologous serum eye drops for dry eye. *Cochrane Database Syst Rev*. 2017;2:CD009327.
142. Espinosa A, Hjorth-Hansen H, Aasly K, Teigum I, Sivertsen G, Seghatchian J. Implementation of a standardised method for the production of allogeneic serum eye drops from regular blood donors in a Norwegian University Hospital: Some methodological aspects and clinical considerations. *Transfus Apher Sci*. 2015;53(1):88-91.
143. Na KS, Kim MS. Allogeneic serum eye drops for the treatment of dry eye patients with chronic graft-versus-host disease. *J Ocul Pharmacol Ther*. 2012;28(5):479-483.
144. Cosar CB, Cohen EJ, Rapuano CJ, et al. Tarsorrhaphy: clinical experience from a cornea practice. *Cornea*. 2001;20(8):787-791.
145. Gould HL. The dry eye and scleral contact lenses. *Am J Ophthalmol*. 1970;70(1):37-41.
146. Krejci L. Scleral gel contact lenses in treatment of dry eyes. *Br J Ophthalmol*. 1972;56(5):425-428.
147. Alipour F, Kheirkhah A, Jabarvand Behrouz M. Use of mini scleral contact lenses in moderate to severe dry eye. *Cont Lens Anterior Eye*. 2012;35(6):272-276.
148. Jacobs DS, Rosenthal P. Boston scleral lens prosthetic device for treatment of severe dry eye in chronic graft-versus-host disease. *Cornea*. 2007;26(10):1195-1199.
149. Nettune GR, Pflugfelder SC. Post-LASIK tear dysfunction and dysesthesia. *Ocul Surf*. 2010;8(3):135-145.
150. Naumann GO, Schlotzer-Schrehardt U. Amantadine-associated corneal edema. *Ophthalmology*. 2009;116(6):1230-1231; author reply 1231.
151. Chuck RS, Jacobs DS, Lee JK, et al. Refractive errors & refractive surgery Preferred Practice Pattern®. *Ophthalmology*. 2018;125(1):P1-P104. [www.aajournal.org/content/preferred-practice-pattern](http://www.aajournal.org/content/preferred-practice-pattern) or [www.aao.org/ppp](http://www.aao.org/ppp).
152. Shimmura S, Shimazaki J, Tsubota K. Results of a population-based questionnaire on the symptoms and lifestyles associated with dry eye. *Cornea*. 1999;18(4):408-411.
153. Lee JT, Teale CW. Development of an economic model to assess costs and outcomes associated with dry eye disease. *Pharmacotherapy* 2000;20:356. Presented at the 2000 Spring Practice and Research Forum of the American College of Clinical Pharmacy; April 2-5, 2000; Monterey, CA.
154. Miljanovic B, Dana R, Sullivan DA, Schaumberg DA. Impact of dry eye syndrome on vision-related quality of life. *Am J Ophthalmol*. 2007;143(3):409-415.
155. Mertzanis P, Abetz L, Rajagopalan K, et al. The relative burden of dry eye in patients' lives: comparisons to a U.S. normative sample. *Invest Ophthalmol Vis Sci*. 2005;46(1):46-50.
156. Schiffman RM, Walt JG, Jacobsen G, Doyle JJ, Lebovics G, Sumner W. Utility assessment among patients with dry eye disease. *Ophthalmology*. 2003;110(7):1412-1419.
157. Li M, Gong L, Sun X, Chapin WJ. Anxiety and depression in patients with dry eye syndrome. *Curr Eye Res*. 2011;36(1):1-7.
158. Galor A, Feuer W, Lee DJ, et al. Depression, post-traumatic stress disorder, and dry eye syndrome: a study utilizing the national United States Veterans Affairs administrative database. *Am J Ophthalmol*. 2012;154(2):340-346.
159. Kim KW, Han SB, Han ER, et al. Association between depression and dry eye disease in an elderly population. *Invest Ophthalmol Vis Sci*. 2011;52(11):7954-7958.

160. Ware JE. *SF-36 Health Survey: Manual and Interpretation Guide*. Boston, MA: The Health Institute; 1993.
161. Hirsch JD. Considerations in the pharmacoeconomics of dry eye. *Manag Care*. 2003;12(12 Suppl):33-38.
162. Reddy P, Grad O, Rajagopalan K. The economic burden of dry eye: a conceptual framework and preliminary assessment. *Cornea*. 2004;23(8):751-761.
163. Kozma CM, Hirsch JD, Wojcik AR. Economic and quality of life impact of dry eye symptoms. *Invest Ophthalmol Vis Sci*. 2000;41:S928.
164. Wojcik AR, Walt JG. Patient-reported outcomes of dry eye symptoms from a Sjogren's syndrome patient survey. *Invest Ophthalmol Vis Sci*. 2002;43:E-Abstract 59.
165. Hirsch JD, Kozma CM, Wojcik AR, Reis B. Economic and quality-of-life impact of dry eye symptoms: a Sjögren's syndrome patient survey. *Invest Ophthalmol Vis Sci*. 1998;39:S65.
166. Nelson JD, Helms H, Fiscella R, Southwell Y, Hirsch JD. A new look at dry eye disease and its treatment. *Adv Ther*. 2000;17(2):84-93.
167. Yu J, Asche CV, Fairchild CJ. The economic burden of dry eye disease in the United States: a decision tree analysis. *Cornea*. 2011;30(4):379-387.
168. The management of dry eye. *Drug Ther Bull*. 2016;54(1):9-12.
169. Jara LJ, Navarro C, Brito-Zeron Mdel P, Garcia-Carrasco M, Escarcega RO, Ramos-Casals M. Thyroid disease in Sjogren's syndrome. *Clin Rheumatol*. 2007;26(10):1601-1606.
170. Manthorpe R, Jacobsson LT, Kirtava Z, Theander E. Epidemiology of Sjogren's syndrome, especially its primary form. *Ann Med Interne (Paris)*. 1998;149(1):7-11.
171. Alamanos Y, Tsifetaki N, Voulgari PV, Venetsanopoulou AI, Siozos C, Drosos AA. Epidemiology of primary Sjogren's syndrome in north-west Greece, 1982-2003. *Rheumatology (Oxford)*. 2006;45(2):187-191.
172. Pillemer SR, Matteson EL, Jacobsson LT, et al. Incidence of physician-diagnosed primary Sjogren syndrome in residents of Olmsted County, Minnesota. *Mayo Clin Proc*. 2001;76(6):593-599.
173. Thomas E, Hay EM, Hajeer A, Silman AJ. Sjogren's syndrome: a community-based study of prevalence and impact. *Br J Rheumatol*. 1998;37(10):1069-1076.
174. Plesivcnik Novljan M, Rozman B, Hocevar A, Grmek M, Kveder T, Tomsic M. Incidence of primary Sjogren's syndrome in Slovenia. *Ann Rheum Dis*. 2004;63(7):874-876.
175. Ioannidis JP, Vassiliou VA, Moutsopoulos HM. Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjogren's syndrome. *Arthritis Rheum*. 2002;46(3):741-747.
176. Theander E, Manthorpe R, Jacobsson LT. Mortality and causes of death in primary Sjogren's syndrome: a prospective cohort study. *Arthritis Rheum*. 2004;50(4):1262-1269.
177. Shiboski CH, Shiboski SC, Seror R, et al. International Sjögren's Syndrome Criteria Working Group. 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren's syndrome: a consensus and data-driven methodology involving three international patient cohorts. *Arthritis Rheumatol*. 2017;69(1):35-45.
178. Shiboski CH, Shiboski SC, Seror R, et al. International Sjögren's Syndrome Criteria Working Group. 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren's syndrome: A consensus and data-driven methodology involving three international patient cohorts. *Ann Rheum Dis*. 2017;76(1):9-16.
179. Foulks GN, Forstot SL, Donshik PC, et al. Clinical guidelines for management of dry eye associated with Sjogren disease. *Ocul Surf*. 2015;13(2):118-132.
180. Akpek EK, Lindsley KB, Adyanthaya RS, Swamy R, Baer AN, McDonnell PJ. Treatment of Sjogren's syndrome-associated dry eye: an evidence-based review. *Ophthalmology*. 2011;118(7):1242-1252.
181. Ramos-Casals M, Tzioufas AG, Stone JH, Siso A, Bosch X. Treatment of primary Sjogren syndrome: a systematic review. *JAMA*. 2010;304(4):452-460.
182. Feenstra RP, Tseng SC. Comparison of fluorescein and rose bengal staining. *Ophthalmology*. 1992;99(4):605-617.
183. Norn MS. Lissamine green. Vital staining of cornea and conjunctiva. *Acta Ophthalmol (Copenh)*. 1973;51(4):483-491.
184. Manning FJ, Wehrly SR, Foulks GN. Patient tolerance and ocular surface staining characteristics of lissamine green versus rose bengal. *Ophthalmology*. 1995;102(12):1953-1957.
185. Machado LM, Castro RS, Fontes BM. Staining patterns in dry eye syndrome: rose bengal versus lissamine green. *Cornea*. 2009;28(7):732-734.
186. Pflugfelder SC, Tseng SC, Yoshino K, Monroy D, Felix C, Reis BL. Correlation of goblet cell density and mucosal epithelial membrane mucin expression with rose bengal staining in patients with ocular irritation. *Ophthalmology*. 1997;104(2):223-235.



187. Farris RL, Gilbard JP, Stuchell RN, Mandel ID. Diagnostic tests in keratoconjunctivitis sicca. *CLAO J*. 1983;9(1):23-28.
188. Lamberts DW, Foster CS, Perry HD. Schirmer test after topical anesthesia and the tear meniscus height in normal eyes. *Arch Ophthalmol*. 1979;97(6):1082-1085.
189. Xu KP, Yagi Y, Toda I, Tsubota K. Tear function index. A new measure of dry eye. *Arch Ophthalmol*. 1995;113(1):84-88.
190. Afonso AA, Monroy D, Stern ME, Feuer WJ, Tseng SC, Pflugfelder SC. Correlation of tear fluorescein clearance and Schirmer test scores with ocular irritation symptoms. *Ophthalmology*. 1999;106(4):803-810.
191. Macri A, Pflugfelder S. Correlation of the Schirmer 1 and fluorescein clearance tests with the severity of corneal epithelial and eyelid disease. *Arch Ophthalmol*. 2000;118(12):1632-1638.
192. Farris RL, Stuchell RN, Mandel ID. Basal and reflex human tear analysis. I. Physical measurements: osmolarity, basal volumes, and reflex flow rate. *Ophthalmology*. 1981;88(8):852-857.
193. Gilbard JP, Farris RL. Ocular surface drying and tear film osmolarity in thyroid eye disease. *Acta Ophthalmol (Copenh)*. 1983;61(1):108-116.
194. Farris RL, Stuchell RN, Mandel ID. Tear osmolarity variation in the dry eye. *Trans Am Ophthalmol Soc*. 1986;84:250-268.
195. Versura P, Profazio V, Campos EC. Performance of tear osmolarity compared to previous diagnostic tests for dry eye diseases. *Curr Eye Res*. 2010;35(7):553-564.
196. Tomlinson A, Khanal S, Ramaesh K, Diaper C, McFadyen A. Tear film osmolarity: determination of a referent for dry eye diagnosis. *Invest Ophthalmol Vis Sci*. 2006;47(10):4309-4315.
197. Jacobi C, Jacobi A, Kruse FE, Cursiefen C. Tear film osmolarity measurements in dry eye disease using electrical impedance technology. *Cornea*. 2011;30(12):1289-1292.
198. See CW, Bilonick RA, Feuer WJ, Galor A. Comparison of two methods for composite score generation in dry eye syndrome. *Invest Ophthalmol Vis Sci*. 2013;54(9):6280-6286.
199. Nelson JD, Farris RL. Sodium hyaluronate and polyvinyl alcohol artificial tear preparations. A comparison in patients with keratoconjunctivitis sicca. *Arch Ophthalmol*. 1988;106(4):484-487.
200. Larmo PS, Jarvinen RL, Setälä NL, et al. Oral sea buckthorn oil attenuates tear film osmolarity and symptoms in individuals with dry eye. *J Nutr*. 2010;140(8):1462-1468.
201. Sullivan BD, Crews LA, Sonmez B, et al. Clinical utility of objective tests for dry eye disease: variability over time and implications for clinical trials and disease management. *Cornea*. 2012;31(9):1000-1008.
202. Bunya VY, Langelier N, Chen S, Pistilli M, Vivino FB, Massaro-Giordano G. Tear osmolarity in Sjogren syndrome. *Cornea*. 2013;32(7):922-927.
203. Mathews PM, Karakus S, Agrawal D, Hindman HB, Ramulu PY, Akpek EK. Tear osmolarity and correlation with ocular surface parameters in patients with dry eye. *Cornea*. 2017;36(11):1352-1357.